




113/2004/575



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

P. Mahoney
9 January 2004

Executive Agency of the Department of Trade and Industry

BEST AVAILABLE COPY

NZAS-0212078

88

Patents Form 1/77

Patents Act 1977
(Rule 16)



20 JAN 03 17:00:22 062266
P01/7700 0.00-0301118.6

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

P015577GB AAW

2. Patent application number

(The Patent Office will fill in this part)

0301118.6 ✓

17 JAN 2003 ✓

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Danisco A/S
Langebrogade 1
PO Box 17
DK-1001 Copenhagen K
Denmark

Patents ADP number (if you know it)

5660873002

If the applicant is a corporate body, give the country/state of its incorporation

Denmark

4. Title of the invention

METHOD

5. Name of your agent (if you have one)

D Young & Co

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

21 New Fetter Lane
London
EC4A 1DA

Patents ADP number (if you know it)

59006 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

NZAS-0212079

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form 0

Description 66

Claim(s) 3

Abstract 1 DM

Drawing(s) 14 T14

10. If you are also filing any of the following, state how many against each item.

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents None
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature *D Young & Co* Date 17 January 2003
D Young & Co (Agents for the Applicants)

12. Name and daytime telephone number of person to contact in the United Kingdom David Alcock 023 8071 9500

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

Patents Form 1/77

NZAS-0212080

METHOD

FIELD OF INVENTION

5 The present invention relates to a method for the *in situ* production of an emulsifier within a foodstuff by use of a lipid:sterol acyltransferase.

The present invention further relates to a method for the *in situ* production of an emulsifier within a foodstuff by use of a lipid:sterol acyltransferase, wherein the method is such that the emulsifier is produced without increasing or substantially
10 without increasing the free fatty acids in the foodstuff.

TECHNICAL BACKGROUND

WO00/05396 teaches a process for preparing a foodstuff comprising an emulsifier,
15 wherein food material is contacted with an enzyme such that an emulsifier is generated by the enzyme from a fatty acid ester and a second functional ingredient is generated from a second constituent. WO00/05396 teaches the use of a lipase or esterase enzyme. Nowhere in WO00/05396 is the specific use of a lipid:sterol acyltransferase taught.

20

The use of lipases (EC. 3.1.1.x) in the food and/or feed industries, for example in foods and/or feeds comprising cereals and, in particular in bread production, has been considered. For instance, in EP 0 585 988 it is claimed that lipase addition to dough resulted in an improvement in the antistaling effect. It is suggested that a lipase
25 obtained from *Rhizopus arrhizus* when added to dough can improve the quality of the resultant bread when used in combination with shortening/fat. WO94/04035 teaches that an improved softness can be obtained by adding a lipase to dough without the addition of any additional fat/oil to the dough. Castello, P. ESEGP 89-10 Dec. 1999 Helsinki, shows that exogenous lipases can modify bread volume.

30

The substrate for lipases in wheat flour is 1.5-3% endogenous wheat lipids, which are a complex mixture of polar and non-polar lipids. The polar lipids can be divided into glycolipids and phospholipids. These lipids are built up of glycerol esterified with two fatty acids and a polar group. The polar group contributes to surface activity of these lipids. Enzymatic cleavage of one of the fatty acids in these lipids leads to lipids with a much higher surface activity. It is well known that emulsifiers, such as DATEM, with high surface activity are very functional when added to dough.

In addition, phospholipases, particularly phospholipase A2 (E.C. 3.1.1.4), have been used for many years for the treatment of egg or egg-based products (see US 4,034,124 and Dutihl & Groger 1981 J. Sci. Food Agric. 32, 451-458 for example). The phospholipase activity during the treatment of egg or egg-based products results in the accumulation of polar lysolecithin, which can act as an emulsifier. Phospholipase treatment of egg or egg-based products can improve the stability, thermal stability under heat treatment such as pasteurisation and result in substantial thickening. Egg-based products may include, but are not limited to cake, mayonnaise, salad dressings, sauces, ice creams and the like.

However, it has also been found that under certain conditions the use of lipases (E.C. 3.1.1.X) in foodstuffs, particularly for example the use of phospholipases (E.C. 3.1.1.4) for the treatment of egg or egg-based products, may have detrimental consequences, such as the production of off-flavours. In addition, the use of lipases (E.C. 3.1.1.X) in dough products may have a detrimental impact on yeast activity, and/or a negative effect on bread volume. The negative effect on bread volume is often explained by overdosing. Overdosing can lead to a decrease in gluten elasticity which results in a dough which is too stiff and thus results in reduced volumes. In addition, or alternatively, such lipases can degrade shortening, oil or milk fat added to the dough. The disadvantages associated with the use of lipases, including phospholipases, may be caused by the build-up of free fatty acids released from the lipids.

Lipase:cholesterol acyltransferases have been known for some time (see for example Buckley - Biochemistry 1983, 22, 5490-5493). In particular, glycerophospholipid:cholesterol acyl transferases (GCATs) have been found, which like the plant and/or mammalian lecithin:cholesterol acyltransferases (LCATs), will
5 catalyse fatty acid transfer between phosphatidylcholine and cholesterol.

Upton and Buckley (TIBS 20, May 1995 p 178-179) and Brumlik and Buckley (J. of Bacteriology Apr. 1996 p 2060-2064) teach a lipase/acyltransferase from *Aeromonas hydrophila* which has the ability to carry out acyl transfer to alcohol acceptors in
10 aqueous media.

SUMMARY ASPECTS OF THE PRESENT INVENTION

According to a first aspect of the present invention there is provided a method of *in situ* production of an emulsifier in a foodstuff, wherein the method comprises the step
15 of adding to the foodstuff a lipid:sterol acyltransferase as defined herein.

In a further aspect, the present invention provides a method of *in situ* production of an emulsifier in a foodstuff, wherein the method is such that the emulsifier is produced
20 without increasing or substantially without increasing the free fatty acids in the foodstuff, and wherein the method comprises the step of adding a lipid:sterol acyltransferase to the foodstuff.

In another aspect, the present invention provides a method of *in situ* production of an
25 emulsifier and either a sterol ester and/or a stanol ester in a foodstuff, wherein the method is such that the emulsifier is produced without increasing or substantially without increasing the free fatty acids in the foodstuff, and wherein the method comprises the step of adding a lipid:sterol acyltransferase to the foodstuff.

30 According to a further aspect of the present invention there is provided a method of *in situ* production of at least two emulsifiers and either a sterol ester and/or a stanol ester in a foodstuff, wherein the method is such that the emulsifiers are produced without

increasing or substantially without increasing the free fatty acids in the foodstuff, and wherein the method comprises the step of adding a lipid:sterol acyltransferase to the foodstuff.

- 5 According to a further aspect of the present invention there is provided a method of production of a foodstuff comprising an emulsifier, wherein the method comprises the step of adding to the foodstuff a lipid:sterol acyltransferase as defined herein.

10 In a further aspect, the present invention provides a method of production of a foodstuff comprising an emulsifier, wherein the method is such that the emulsifier is produced without increasing or substantially without increasing the free fatty acids in the foodstuff, and wherein the method comprises the step of adding a lipid:sterol acyltransferase to the foodstuff.

- 15 In another aspect, the present invention provides a method of the production of a foodstuff comprising an emulsifier and either a sterol ester and/or a stanol ester, wherein the method is such that the emulsifier is produced without increasing or substantially without increasing the free fatty acids in the foodstuff, and wherein the method comprises the step of adding a lipid:sterol acyltransferase to the foodstuff.

20 According to a further aspect of the present invention there is provided a method of the production of a foodstuff comprising at least two emulsifiers and either a sterol ester and/or a stanol ester, wherein the method is such that the emulsifiers are produced without increasing or substantially without increasing the free fatty acids in the
25 foodstuff, and wherein the method comprises the step of adding a lipid:sterol acyltransferase to the foodstuff.

In another aspect, the present invention provides use of a lipid:sterol acyltransferase to prepare from a food material a foodstuff comprising an emulsifier, wherein the
30 emulsifier is generated from constituents of the food material by the lipid:sterol acyltransferase.

In a further aspect, the present invention provides use of a lipid:sterol acyltransferase to prepare from a food material a foodstuff comprising an emulsifier, wherein the emulsifier is produced without increasing or substantially without increasing the free fatty acids in the foodstuff, and wherein the emulsifier is generated from constituents of the food material by the lipid:sterol acyltransferase.

In another aspect, the present invention provides use of a lipid:sterol acyltransferase to prepare from a food material a foodstuff comprising an emulsifier and either a sterol ester and/or a stanol ester, wherein the emulsifier is produced without increasing or substantially without increasing the free fatty acids in the foodstuff, and wherein the emulsifier and/or sterol ester and/or stanol ester is/are generated from constituents of the food material by the lipid:sterol acyltransferase.

According to a further aspect of the present invention there is provided use of a lipid:sterol acyltransferase to prepare from a food material a foodstuff comprising at least two emulsifiers and either a sterol ester and/or a stanol ester, wherein the emulsifiers are produced without increasing or substantially without increasing the free fatty acids in the foodstuff, and wherein one or both of the emulsifiers and/or the sterol ester and/or the stanol ester is/are generated from constituents of the food material by the lipid:sterol acyltransferase.

In accordance with a further aspect of the present invention there is provided a method of the *in situ* production of an emulsifier, preferably a lysolecithin and a sterol ester in a egg based foodstuff, wherein the method is such that the emulsifier is produced without increasing or substantially without increasing the free fatty acids in the foodstuff, and wherein the method comprises the step of adding a lipid:sterol acyltransferase to the foodstuff.

In another aspect, the present invention provides a method of production of a egg based foodstuff comprising an emulsifier, preferably a lysolecithin and a sterol ester in a egg based foodstuff, wherein the emulsifier is produced without increasing or

substantially without increasing the free fatty acids in the foodstuff, and wherein the method comprises the step of adding a lipid:sterol acyltransferase to the foodstuff.

5 In a further aspect, the present invention further provides a foodstuff obtainable by, preferably obtained by, a method according to the present invention.

DETAILED ASPECTS OF THE PRESENT INVENTION

10 The term "lipid:sterol acyltransferase" as used herein means an enzyme which as well as having lipase activity (generally classified as E.C. 3.1.1.x in accordance with the Enzyme Nomenclature Recommendations (1992) of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology) also has acyltransferase activity (generally classified as E.C. 2.3.1.x), whereby the enzyme is capable of transferring an acyl group from a lipid to a sterol and/or a stanol.

15 Preferably, the lipid substrate upon which the lipid:sterol acyltransferase according to the present invention acts is one or more of the following lipids: a phospholipid, such as phosphatidylcholine for example, a triacylglyceride, a diglyceride, or a glycolipid, such as digalactosyldiglyceride (DGDG). This lipid substrate may be referred to
20 herein as the "lipid acyl donor". The term phosphatidylcholine as used herein is synonymous with the term lecithin and these terms may be used herein interchangeably.

25 Preferably the lipid substrate is a food lipid, that is to say a lipid component of a foodstuff.

For some aspects, preferably the lipid substrate upon which the lipid:sterol acyltransferase acts is a phospholipid, such as phosphatidylcholine.

30 For some aspects, preferably the lipid substrate is a glycolipid, such as DGDG for example.

For some aspects, preferably the lipid:sterol acyltransferase according to the present invention is incapable, or substantially incapable, of acting on a triglyceride and/or a 1-monoglyceride.

- 5 Suitably, the lipid substrate or lipid acyl donor may be one or more lipids present in one or more of the following substrates: fats, including lard, tallow and butter fat; oils including oils extracted from or derived from palm oil, sunflower oil, soya bean oil, safflower oil, cotton seed oil, ground nut oil, corn oil, olive oil, peanut oil, coconut oil, and rape seed oil. Lecithin from soya, rape seed or egg yolk is also a suitable lipid
- 10 substrate. The lipid substrate may be an oat lipid or other plant based material containing galactolipids.

In one aspect the lipid acyl donor is preferably lecithin (phosphatidylcholine) in egg yolk.

15

For some aspects of the present invention, the lipid may be selected from lipids having a fatty acid chain length of from 8 to 22 carbons.

- For some aspects of the present invention, the lipid may be selected from lipids having a fatty acid chain length of from 16 to 22 carbons, more preferably of from 16 to 20 carbons.
- 20

- For some aspect of the present invention, the lipid may be selected from lipids having a fatty acid chain length of no greater than 14 carbons, suitably from lipids having a fatty acid chain length of from 4 to 14 carbons, suitably 4 to 10 carbons, suitably 4 to 8 carbons.
- 25

- Suitably, the lipid:sterol acyltransferase according to the present invention may exhibit one or more of the following lipase activities: glycolipase activity (E.C. 3.1.1.26), triacylglycerol lipase activity (E.C. 3.1.1.3), phospholipase A2 activity (E.C. 3.1.1.4) or phospholipase A1 activity (E.C. 3.1.1.32). The term "glycolipase activity" as used herein encompasses "galactolipase activity".
- 30

Suitably, the lipid:sterol acyltransferase according to the present invention may have at least one or more of the following activities: glycolipase activity (E.C. 3.1.1.26) and/or phospholipase A1 activity (E.C. 3.1.1.32) and/or phospholipase A2 activity (E.C. 3.1.1.4):

For some aspects, the lipid:sterol acyltransferase according to the present invention may have at least glycolipase activity (E.C. 3.1.1.26).

Suitably, for some aspects the lipid:sterol acyltransferase according to the present invention may be capable of transferring an acyl group from a glycolipid to a sterol and/or a stanol to form a sterol and/or a stanol ester.

In one aspect, preferably the lipid:sterol acyltransferase according to the present invention does not have triacylglycerol lipase activity (E.C. 3.1.1.3).

The lipid:sterol acyltransferase is capable of transferring an acyl group from a lipid to a sterol and/or a stanol. Thus, the "acyl acceptor" according to the present invention may be either a sterol or a stanol or a combination of both a sterol and a stanol.

Suitable sterol acyl acceptors include cholesterol and phytosterols, for example alpha-sitosterol, beta-sitosterol, stigmasterol, ergosterol, campesterol, 5,6-dihydrosterol, brassicasterol, alpha-spinasterol, beta-spinasterol, gamma-spinasterol, deltaspinasterol, fucosterol, dimosterol, ascosterol, serebisterol, episterol, anasterol, hyposterol, chondrillasterol, desmosterol, chalinosterol, poriferasterol, clionasterol, and other natural or synthetic isomeric forms and derivatives.

In one aspect, preferably the sterol acyl acceptor is one or more of the following: alpha-sitosterol, beta-sitosterol, stigmasterol, ergosterol and campesterol.

In one aspect, preferably the sterol acyl acceptor is cholesterol. When it is the case that cholesterol is the acyl acceptor for the lipid:sterol acyltransferase, the amount of

free cholesterol in the foodstuff is reduced as compared with the foodstuff prior to exposure to the lipid:sterol acyltransferase and/or as compared with an equivalent foodstuff which has not been treated with the lipid:sterol acyltransferase.

- 5 Suitable stanol acyl acceptors include phytosterols, for example beta-sitosterol or ss-sitosterol.

In one aspect, preferably the sterol and/or stanol acyl acceptor is a sterol and/or a stanol other than cholesterol.

10

In some aspects, the foodstuff prepared in accordance with the present invention may be used to reduce blood serum cholesterol and/or to reduce low density lipoprotein. Blood serum cholesterol and low density lipoproteins have both been associated with certain diseases in humans, such as atherosclerosis and/or heart disease for example.

- 15 Thus, it is envisaged that the foodstuffs prepared in accordance with the present invention may be used to reduce the risk of such diseases.

Thus, in one aspect the present invention provides the use of a foodstuff according to the present invention for use in the treatment and/or prevention of atherosclerosis and/or heart disease.

20

In a further aspect, the present invention provides a medicament comprising a foodstuff according to the present invention.

- 25 In a further aspect, the present invention provides a method of treating and/or preventing a disease in a human or animal patient which method comprising administering to the patient an effective amount of a foodstuff according to the present invention.

- 30 Suitably, the sterol and/or the stanol "acyl acceptor" may be found naturally within the foodstuff. Alternatively, the sterol and/or the stanol may be added to the foodstuff. When it is the case that a sterol and/or a stanol is added to the foodstuff, the sterol

and/or stanol may be added before, simultaneously with, and/or after the addition of the lipid:sterol acyltransferase according to the present invention. Suitably, the present invention may encompass the addition of exogenous sterols/stanols, particularly phytosterols/phytostanols, to the foodstuff prior to or simultaneously with the addition
5 of the enzyme according to the present invention.

For some aspects, one or more sterols present in the foodstuff may be converted to one or more stanols prior to or at the same time as the lipid:sterol acyltransferase is added according to the present invention. Any suitable method for converting sterols to
10 stanols may be employed. The conversion may be conducted prior to the addition of the lipid:sterol acyltransferase in accordance with the present invention or simultaneously with the addition of the lipid:sterol acyltransferase in accordance with the present invention. Suitably enzymes for the conversion of sterol to stanols are taught in WO00/061771.

15 Suitably the present invention may be employed to produce phytostanol esters *in situ* in a foodstuff. Phytostanol esters are considered to have increased solubility, bioavailability and enhanced health benefits (see for example WO92/99640).

20 In some embodiments of the present invention the stanol ester and/or the sterol ester may be a flavouring and/or a texturiser. In which instances, the present invention encompasses the *in situ* production of flavourings and/or texturisers.

Thus in accordance with the present invention, one or more of the following
25 advantageous properties can be achieved: *in situ* production of an emulsifier without an increase in free fatty acids; a reduction in the accumulation of free fatty acids in the foodstuff; a reduction in free cholesterol levels in the foodstuff; an increase in sterol esters and/or stanol esters; a reduction in blood serum cholesterol and/or low density lipoproteins.

30 An advantage of the present invention is that the emulsifier(s) is/are prepared *in situ* in the foodstuff without an increase in the free fatty acid content of the foodstuff. The

production of free fatty acids can be detrimental to foodstuffs. In particular, free fatty acids have been linked with off-odours and/or off-flavours in foodstuffs, as well other detrimental effects, including a soapy taste in cheese for instance. Preferably, the method according to the present invention results in the *in situ* preparation of an emulsifier(s) wherein the accumulation of free fatty acids is reduced and/or eliminated. Without wishing to be bound by theory, in accordance with the present invention the fatty acid which is removed from the lipid is transferred by the lipid:sterol acyltransferase to a sterol and/or a stanol. Thus, the overall level of free fatty acids in the foodstuff does not increase or increases only to an insignificant degree. This is in sharp contradistinction to the situation when lipase (E.C. 3.1.1.x) are used to produce emulsifiers *in situ*. In particular, the use of lipases can result in an increased amount of free fatty acid in the foodstuff, which can be detrimental. In accordance with the present invention, the accumulation of free fatty acids is reduced and/or eliminated when compared with the amount of free fatty acids which would have been accumulated had a lipase enzyme, in particular a phospholipase A₂ enzyme, been used in place of the lipid:sterol acyltransferase in accordance with the present invention.

Preferably, the lipid:sterol acyltransferase enzyme according to the present invention may be characterised using the following criteria:

- (i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a lipid acyl donor is transferred to a sterol and/or a stanol acyl acceptor to form a new ester, i.e. a sterol ester and/or a stanol ester; and
- (ii) the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.

Preferably, X of the GDSX motif is L. Thus, preferably the enzyme according to the present invention comprises the amino acid sequence motif GSDL.

The GDSX motif is comprised of four conserved amino acids. Preferably, the serine within the motif is a catalytic serine of the lipid:sterol acyltransferase enzyme.

Suitably, the serine of the GDSX motif may be in a position corresponding to Ser-16 in *Aeromonas hydrophila* lipolytic enzyme taught in Brumlik & Buckley (Journal of Bacteriology Apr. 1996, Vol. 178, No. 7, p 2060-2064).

- 5 To determine if a protein has the GDSX motif according to the present invention, the sequence is preferably compared with the hidden markov model profiles (HMM profiles) of the pfam database. A hidden markov model profile is based on a manually verified multiple sequence alignment of a representative set of sequences comprising a protein domain family, and is used for alignment purposes. A positive match with the
- 10 hidden markov model profile (HMM profile) of the pfam00657.6 domain family indicates the presence of the GDSL or GDSX domain according to the present invention. For a detailed explanation of the theory and implementation of hidden markov models see Durbin *et al* 1998 Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids, Cambridge Uni. Press, ISBN: 0-521-62051-4.
- 15 For pfam alignment and scoring procedures see [A. Bateman *et al*: Nucleic Acids Research, 30(1):276-280, 2002]. The pfam database can be accessed through the internet and is currently available at one of the following web pages:
<http://www.sanger.ac.uk/Software/Pfam/index.shtml>
<http://pfam.wustl.edu/>
- 20 <http://www.cgr.ki.se/Pfam/>
<http://pfam.joury.inra.fr/>

The pfam00657.6 GDSX domain is a unique identifier which distinguishes proteins possessing this domain from other enzymes.

25

The pfam00657.6 consensus sequence is presented in Figure 1 as SEQ ID No. 1.

Preferably, the lipid:sterol acyltransferase enzyme according to the present invention may be characterised using the following criteria:

- 30 (i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of

a lipid acyl donor is transferred to a sterol and/or a stanol acyl acceptor to form a new ester, i.e. a sterol ester and/or a stanol ester;

- (ii) the enzyme comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S;
- (iii) the enzyme comprises His-309 or comprises a histidine residue at a position corresponding to His-309 in the *Aeromonas hydrophila* lipolytic enzyme shown in Figure 2 (SEQ ID No. 2).

10 Preferably, the amino acid residue X of the GDSX motif is L.

In SEQ ID No. 2 the first 18 amino acid residues form a signal sequence. His-309 of the full length sequence, that is the protein including the signal sequence, equates to His-291 of the mature part of the protein, i.e. the sequence without the signal sequence.

Preferably, the lipid:sterol acyltransferase enzyme according to the present invention comprises the following catalytic triad: Ser-34, Asp-134 and His-309 or comprises a serine residue, an aspartic acid residue and a histidine residue, respectively, at positions corresponding to Ser-34, Asp-134 and His-309 in the *Aeromonas hydrophila* lipolytic enzyme shown in Figure 2 (SEQ ID No. 2). As stated above, in the sequence shown in SEQ ID No. 2 the first 18 amino acid residues form a signal sequence. Ser-34, Asp-134 and His-309 of the full length sequence, that is the protein including the signal sequence, equate to Ser-16, Asp-116 and His-291 of the mature part of the protein, i.e. the sequence without the signal sequence. In the pfam00657.6 consensus sequence, as given in Figure 1 (SEQ ID No. 1) the active site residues correspond to Ser-7, Asp-157 and His-348.

Preferably, the lipid:sterol acyltransferase enzyme according to the present invention may be characterised using the following criteria:

- (i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of

- a first lipid acyl donor is transferred to a sterol and/or a stanol acyl acceptor to form a new ester, i.e. a sterol ester and/or a stanol ester; and
- (ii) the enzyme comprises at least Gly-32, Asp-33, Ser-34, Asp-134 and His-309 or comprises glycine, aspartic acid, serine, aspartic acid and histidine residues at positions corresponding to Gly-32, Asp-33, Ser-34, Asp-134 and His-309, respectively, in the *Aeromonas hydrophila* lipolytic enzyme shown in Figure 2 (SEQ ID No. 2).

Suitably, the lipid:sterol acyltransferase enzyme according to the present invention may be characterised using the following criteria:

- (i) the enzyme possesses acyl transferase activity which may be defined as ester transfer activity whereby the acyl part of an original ester bond of a first lipid acyl donor is transferred to a sterol and/or a stanol acyl acceptor to form a new ester, i.e. a sterol ester and/or a stanol ester; and
- (ii) the enzyme comprises Gly-5, Asp-6, Ser-7, Asp-157 and His-348 or comprises glycine, aspartic acid, serine, aspartic acid and histidine residues at positions corresponding to Gly-5, Asp-6, Ser-7, Asp-156 and His-348, respectively, in the pfam00657.6 consensus sequence shown in Figure 1 (SEQ ID No. 1).

20

Suitably, the lipid:sterol acyltransferase enzyme according to the present invention may be obtainable, preferably obtained, from organisms from one or more of the following genera: *Aeromonas*, *Streptomyces*, *Saccharomyces*, *Lactococcus*, *Mycobacterium*, *Streptococcus*, *Lactobacillus*, *Desulfotobacterium*, *Bacillus*, *Campylobacter*, *Vibrionaceae*, *Xylella*, *Sulfolobus*, *Aspergillus*, *Schizosaccharomyces*, *Listeria*, *Neisseria*, *Mesorhizobium*, *Ralstonia*, *Xanthomonas* and *Candida*.

Suitably, the lipid:sterol acyltransferase enzyme according to the present invention may be obtainable, preferably obtained, from one or more of the following organisms:

Aeromonas hydrophila, *Aeromonas salmonicida*, *Streptomyces coelicolor*, *Mycobacterium*, *Streptococcus pyogenes*, *Lactococcus lactis*, *Streptococcus pyogenes*, *Streptococcus thermophilus*, *Lactobacillus helveticus*, *Desulfotobacterium*

dehalogenans, *Bacillus* sp., *Campylobacter jejuni*, *Vibrionaceae*, *Xylella fastidiosa*,
Sulfolobus solfataricus, *Saccharomyces cerevisiae*, *Aspergillus terreus*,
Schizosaccharomyces pombe, *Listeria innocua*, *Listeria monocytogenes*, *Neisseria*
meningitidis, *Mesorhizobium loti*, *Ralstonia solanacearum*, *Xanthomonas campestris*,
5 *Xanthomonas axonopodis* and *Candida parapsilosis*.

Suitably, the lipid:sterol acyltransferase enzyme according to the present invention
comprises one or more of the following amino acid sequences:

- (i) the amino acid sequence shown as SEQ ID No. 2 (see Figure 2)
- 10 (ii) the amino acid sequence shown as SEQ ID No. 3 (see Figure 3)
- (iii) the amino acid sequence shown as SEQ ID No. 4 (see Figure 4)
- (iv) the amino acid sequence shown as SEQ ID No. 5 (see Figure 5)
- (v) the amino acid sequence shown as SEQ ID No. 6 (see Figure 6)
- (vi) the amino acid sequence shown as SEQ ID No. 12 (see Figure 14)
- 15 (vii) an amino acid sequence which has 75% or more identity with any one of the
sequences shown as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No.
5, SEQ ID No. 6 or SEQ ID No. 12.

Suitably, the lipid:sterol acyltransferase enzyme according to the present invention
20 comprises either the amino acid sequence shown as SEQ ID No. 2 or as SEQ ID No. 3
or comprises an amino acid sequence which has 75% or more identity with either the
amino acid sequence shown as SEQ ID No. 2 or the amino acid sequence shown as
SEQ ID No. 3.

25 For the purposes of the present invention, the degree of identity is based on the number
of sequence elements which are the same. The degree of identity in accordance with
the present invention may be suitably determined by means of computer programs
known in the art, such as GAP provided in the GCG program package (Program
Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer
30 Group, 575 Science Drive, Madison, Wisconsin, US53711) (Needleman & Wunsch
(1970), J. of Molecular Biology 48, 443-45) using the following settings for

polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.

5 Suitably the lipid:sterol acyltransferase enzyme according to the present invention comprises an amino acid sequence which has 80% or more, preferably 85% or more, more preferably 90% or more and even more preferably 95% or more identity with any one of the sequences shown as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6 or SEQ ID No. 12.

10 Suitably, the lipid:sterol acyltransferase enzyme according to the present invention comprises one or more of the following amino acid sequences:

- (a) an amino acid sequence shown as amino acid residues 1-100 of SEQ ID No. 2;
- (b) an amino acid sequence shown as amino acids residues 101-200 of SEQ ID No. 2;
- (c) an amino acid sequence shown as amino acid residues 201-300 of SEQ ID No. 2;

15 or

- (d) an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more identity to any one of the amino acid sequences defined in (a)-(c) above.

20 Suitably, the lipid:sterol acyltransferase enzyme according to the present invention comprises one or more of the following amino acid sequences:

- (a) an amino acid sequence shown as amino acid residues 28-39 of SEQ ID No. 2;
- (b) an amino acid sequence shown as amino acids residues 77-88 of SEQ ID No. 2;
- (c) an amino acid sequence shown as amino acid residues 126-136 of SEQ ID No. 2;
- 25 (d) an amino acid sequence shown as amino acid residues 163-175 of SEQ ID No. 2;
- (e) an amino acid sequence shown as amino acid residues 304-311 of SEQ ID No. 2;

or

- (f) an amino acid sequence which has 75% or more, preferably 85% or more, more preferably 90% or more, even more preferably 95% or more identity to any one of
- 30 the amino acid sequences defined in (a)-(e) above.

Suitably, the lipid:sterol acyltransferase enzyme according to the present invention may comprise an amino acid sequence produced by the expression or one or more of the following nucleotide sequences:

- (a) the nucleotide sequence shown as SEQ ID No. 7 (see Figure 9);
- 5 (b) the nucleotide sequence shown as SEQ ID No. 8 (see Figure 10);
- (c) the nucleotide sequence shown as SEQ ID No. 9 (see Figure 11);
- (d) the nucleotide sequence shown as SEQ ID No. 10 (see Figure 12);
- (e) the nucleotide sequence shown as SEQ ID No. 11 (see Figure 13);
- (f) the nucleotide sequence shown as SEQ ID No. 13 (see Figure 15); or
- 10 a nucleotide sequence which has 75% or more identity with any one of the sequences shown as SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11 or SEQ ID No. 13.

Suitably the nucleotide sequence may have 80% or more, preferably 85% or more, 15 more preferably 90% or more and even more preferably 95% or more identity with any one of the sequences shown as SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11 or SEQ ID No. 13.

In one aspect, the lipid:sterol acyltransferase according to the present invention may be 20 a lecithin:cholesterol acyltransferases (LCAT).

Suitable LCATs are known in the art and may be obtainable from one or more of the following organisms for example: mammals, rat, mice, chickens, *Drosophila melanogaster*, plants, including *Arabidopsis* and *Oryza sativa*, nematodes, fungi and 25 yeast.

The term "without increasing or without substantially increasing the free fatty acids" as used herein means that preferably the lipid:sterol acyl transferase according to the present invention has 100% transferase activity (i.e. transfers 100% of the acyl groups 30 from an acyl donor onto the sterol/stanol acyl acceptor, with no hydrolytic activity); however, the enzyme may transfer less than 100% of the acyl groups present in the lipid acyl donor to the sterol/stanol. In which case, preferably the acyltransferase

activity accounts for at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, more preferably 50%, more preferably at least 60%, more preferably at least 70%, more preferably at least 80%, more preferably at least 90% and more preferably at least 98% of the total enzyme activity. The % transferase activity (i.e. the transferase activity as a percentage of the total enzymatic activity) may be determined by the following protocol:

Protocol for the determination of % acyltransferase activity:

A foodstuff to which a lipid:sterol acyltransferase according to the present invention has been added may be extracted following the enzymatic reaction with $\text{CHCl}_3:\text{CH}_3\text{OH}$ 2:1 and the organic phase containing the lipid material is isolated and analysed by GLC and HPLC according to the procedure detailed hereinbelow. From the GLC and HPLC analyses the amount of free fatty acids and sterol/stanol esters are determined. A control foodstuff to which no enzyme according to the present invention has been added, is analysed in the same way.

Calculation:

From the results of the GLC and HPLC analyses the increase in free fatty acids and sterol/stanol esters can be calculated:

$$\Delta \% \text{ fatty acid} = \% \text{ Fatty acid(enzyme)} - \% \text{ fatty acid(control)}$$

$$\Delta \% \text{ sterol ester} = \% \text{ sterol/stanol ester(enzyme)} - \% \text{ sterol/stanol ester(control)}$$

The transferase activity is calculated as a percentage of the total enzymatic activity:

$$\% \text{ transferase activity} = \frac{\Delta \% \text{ sterol ester}/(\text{Mv sterol ester}) \times 100}{\Delta \% \text{ sterol ester}/(\text{Mv sterol ester}) + \Delta \% \text{ fatty acid}/(\text{Mv fatty acid})}$$

where:

Mv sterol ester = average molecular weight of the sterol/stanol esters

Mv fatty acid = average molecular weight of the fatty acids

If the free fatty acids are increased in the foodstuff they are preferably not increased to a significant degree. By this we mean, that the increase in free fatty acid does not adversely affect the quality of the foodstuff.

In some aspects of the present invention the amount of free fatty acid in the foodstuff may even be reduced (as compared with the amount of free fatty acid that would be produced if a phospholipase A2 enzyme had been used.

10

The term "*in situ*" as used herein means that the emulsifier(s) and/or the sterol/stanol esters are produced within the foodstuff or a fraction of the foodstuff. This contrasts the situation where the emulsifier(s) and/or the sterol/stanol esters are produced separately of the foodstuff and are added as formed products to the foodstuff during preparation of the same. In other words, the term "*in situ*" as used herein means that by the addition of the lipid:sterol acyltransferase enzyme according to the present invention to a foodstuff, or to the food ingredients/materials constituting the foodstuff, an emulsifier and/or a sterol ester and/or a stanol ester may be produced from components of the foodstuff. Suitably, the components of the foodstuff may be the substrate(s) for the enzyme. If necessary, the components of the foodstuff may be supplemented by addition of one or more further components which further components may be the same as those present in the foodstuff or may be additional to those components already present in the foodstuff. For the avoidance of doubt, the method according to the present invention is a method for the production of an emulsifier and/or a sterol ester and/or a stanol ester *in situ* in a foodstuff and is not a method for preparing an emulsifier and/or a sterol ester and/or a stanol ester (for example is an isolated and/or purified form) for subsequent addition to a foodstuff.

Preferably, the lipid:sterol acyltransferase according to the present invention is capable of transferring an acyl group from a lipid to a sterol/stanol when present in a polar environment, preferably in an aqueous environment, preferably a water containing foodstuff. Suitably, however the aqueous environment may be an aqueous buffer. The

term "aqueous environment" as used herein means preferably an environment which is absent an organic solvent, preferably absent a polar organic solvent. In particular, the term "aqueous environment" may refer to an environment to which no exogenous organic solvents, preferably no polar organic solvents, have been added. The term
5 organic solvent as used herein does not encompass food oils that are high in non-polar lipids. Suitably, the aqueous environment according to the present invention may comprise less than 30% by volume organic solvents, more preferably less than 15% by volume organic solvents, more preferably less than 5%. Suitably the foodstuff may comprise between 1 and 5% organic solvent, for example ethanol. However, when the
10 foodstuff comprises such an organic solvent, preferably it is produced endogenously within the foodstuff. That is to say, when the foodstuff comprises such an organic solvent, preferably the organic solvent is not an exogenous organic solvent.

The term "foodstuff" as used herein means a substance which is suitable for human
15 and/or animal consumption.

Suitably, the term "foodstuff" as used herein may mean a foodstuff in a form which is ready for consumption. Alternatively or in addition, however, the term foodstuff as used herein may mean one or more food materials which are used in the preparation of
20 a foodstuff. By way of example only, the term foodstuff encompasses both baked goods produced from dough as well as the dough used in the preparation of said baked goods.

In a preferred aspect the present invention provides a foodstuff as defined above
25 wherein the foodstuff is selected from one or more of the following: eggs, egg-based products, including but not limited to mayonnaise, salad dressings, sauces, ice creams, egg powder, modified egg yolk and products made therefrom; baked goods, including breads, cakes, sweet dough products, laminated doughs, liquid batters, muffins, doughnuts, biscuits, crackers and cookies; confectionery, including chocolate, candies,
30 caramels, halawa, gums, including sugar free and sugar sweetened gums, bubble gum, soft bubble gum, chewing gum and puddings; frozen products including sorbets, preferably frozen dairy products, including ice cream and ice milk; dairy products,

including cheese, butter, milk, coffee cream, whipped cream, custard cream, milk drinks and yoghurts; mousses, whipped vegetable creams, meat products, including processed meat products; edible oils and fats, aerated and non-aerated whipped products, oil-in-water emulsions, water-in-oil emulsions, margarine, shortening and spreads including low fat and very low fat spreads; dressings, mayonnaise, dips, cream based sauces, cream based soups, beverages, spice emulsions, sauces and mayonnaise.

Suitably the foodstuff in accordance with the present invention may be a "fine foods", including cakes, pastry, confectionery, chocolates, fudge and the like.

10

In one aspect the foodstuff in accordance with the present invention may be a dough product or a baked product, such as a bread, a fried product, a snack, cakes, pies, brownies, cookies, noodles, snack items such as crackers, graham crackers, pretzels, and potato chips, and pasta.

15

In a further aspect, the foodstuff in accordance with the present invention may be a plant derived food product such as flours, pre-mixes, oils, fats, cocoa butter, coffee whitener, salad dressings, margarine, spreads, peanut butter, shortenings, ice cream, cooking oils.

20

In another aspect, the foodstuff in accordance with the present invention may be a dairy product, including butter, milk, cream, cheese such as natural, processed, and imitation cheeses in a variety of forms (including shredded, block, slices or grated), cream cheese, ice cream, frozen desserts, yoghurt, yoghurt drinks, butter fat, anhydrous milk fat, other dairy products. The enzyme according to the present invention may improve fat stability in dairy products.

It is particularly advantageous to utilise the present invention in cheese as the production of free fatty acids in cheese is associated with a "soapy" taste. Thus, the use of a lipid:sterol acyltransferase in accordance with the present invention advantageously produces cheese without a "soapy" taste.

30

In another aspect, the foodstuff in accordance with the present invention may be a food product containing animal-derived ingredients, such as processed meat products, cooking oils, shortenings.

- 5 In a further aspect, the foodstuff in accordance with the present invention may be a beverage, a fruit, mixed fruit, a vegetable or wine. In some cases the beverage may contain up to 20 g/l of added phytosterols.

- 10 In another aspect, the foodstuff in accordance with the present invention may be an animal feed. The animal feed may be enriched with phytosterol and/or phytosterols, preferably with beta-sitosterol/stanol. Suitably, the animal feed may be a poultry feed. When the foodstuff is poultry feed, the present invention may be used to lower the cholesterol content of eggs produced by poultry fed on the foodstuff according to the present invention.

- 15 In one aspect preferably the foodstuff is selected from one or more of the following: eggs, egg-based products, including mayonnaise, salad dressings, sauces, ice cream, egg powder, modified egg yolk and products made therefrom.

- 20 Preferably the foodstuff according to the present invention is a water containing foodstuff. Suitably the foodstuff may be comprised of 10-98% water, suitably 14-98%, suitably of 18-98% water, suitably of 20-98%, suitably of 40-98%, suitably of 50-98%, suitably of 70-98%, suitably of 75-98%.

- 25 For some aspects, preferably the foodstuff in accordance with the present invention is not a pure plant derived oil, such as olive oil, sunflower oil, peanut oil, rapeseed oil for instance. For the avoidance of doubt, in some aspects of the present invention the foodstuff according to the present invention may comprise an oil, but preferably the foodstuff is not primarily composed of oil or mixtures of oil. For some aspects,
30 preferably the foodstuff comprises less than 95% lipids, preferably less than 90% lipids, preferably less than 85%, preferably less than 80% lipids. Thus, for some

aspects of the present invention oil may be a component of the foodstuff, but preferably the foodstuff is not a oil *per se*.

The claims of the present invention are to be construed to include each of the
5 foodstuffs listed above.

Suitably, the emulsifier in accordance with the present invention may be for example one or more of the following: a diglyceride, a monoglyceride, such as 1-monoglyceride or a lysophosphatidylcholine. The emulsifier is preferably produced
10 from the lipid acyl donor following removal of one or more acyl groups from said lipid acyl donor. The term lysophosphatidylcholine as used herein is synonymous with the term lysolecithin and these terms may be used herein interchangeably.

The lipase and acyltransferase activity of an enzyme may be evaluated using the
15 following assays. In this way, a lipid:sterol acyltransferase having the enzyme characteristics defined herein may be obtained/identified.

Lipase assay based on tributyrin as substrate (LIPU): Lipase activity based on tributyrin may be measured according to Food Chemical Codex, Forth Edition,
20 National Academy Press, 1996, p 803, with the modification that the sample is dissolved in deionized water instead of glycine buffer, and the pH stat set point is 5.5 instead of 7. 1 LIPU is defined as the quantity of enzyme which can liberate 1 μ mol butyric acid per minute under assay conditions.

25 Lipid:sterol acyltransferase assay for the determination of a lipid:sterol acyltransferase unit, LATU(St): Lipid acyl transferase activity is defined as the amount of μ mol sterol ester formed per minute from lecithin as donor and cholesterol as acceptor molecule under assay conditions using the following procedure: Substrate: 0.6% Avanti phospholipid (95% PC) and 0.4 % cholesterol are dispersed in 0.05M HEPES buffer
30 pH 7 and 5 mM CaCl_2 and heated to 40°C. The mixture is homogenized on a Turrax mixer for 10 seconds. 1 ml substrate is thermostated to 30 °C for 5 minutes. 100 μ l of enzyme solution is added. After 10 minutes the reaction is stopped by adding 0.1 ml

1M HCl. The lipid components are extracted into an organic phase by adding 1 ml $\text{CHCl}_3:\text{CH}_3\text{OH}$ 2:1. 500 μl of the organic phase is transferred to a 10 ml flask and evaporated at 60°C in a stream of nitrogen. The amount of cholesterol ester formed is determined by GLC analyses, using cholesterol oleate (>95%) as standard.

5

Preferably the method and/or use according to the present invention may be carried out in foodstuff at a temperature of 15-60°C, preferably at a temperature of 20-60°C. For some aspects, for example in dough, preferably the temperature of the food during which the acyltransferase reaction takes place is between 20 and 40°C. For other

10

aspects, for example with regard to dairy products, such as cheese, the temperature of the food may suitably be between 30°C and 60°C. In yet other aspects, for example with regard to mayonnaise, the temperature of the food may suitably be between 20 and 40°C, more preferably between 25 and 30°C.

15

Preferably, the emulsifier produced according to the present invention comprises less than 5 wt % of the foodstuff.

Preferably, the emulsifier produced according to the present invention comprises from 0.01 to 4 wt % of the foodstuff.

20

Preferably, the emulsifier produced according to the present invention comprises from 0.01 to 2 wt % of the foodstuff.

Preferably, the emulsifier produced according to the present invention comprises from

25

0.01 to 1 wt % of the foodstuff.

Preferably, the emulsifier produced according to the present invention comprises from 0.01 to 0.5 wt % of the foodstuff.

30

Preferably, the emulsifier produced according to the present invention comprises from 0.01 to 0.3 wt % of the foodstuff.

Suitably, the method according to the present invention includes inactivating or denaturing the enzyme to provide a foodstuff comprising the enzyme in an inactive or denatured form. Suitably the enzyme may be denatured by either baking or by pasteurisation.

5

Preferably the enzyme according to the present invention is present in an inactive form or in a denatured form in the foodstuff.

10 The enzyme according to the present invention is preferably not immobilised, in particular is not immobilised on a solid support.

The enzyme according to the present invention may be used with one or more other suitable food grade enzymes. Thus, it is within the scope of the present invention that, in addition to the enzyme of the invention, at least one further enzyme is added to the
15 foodstuff. Such further enzymes include starch degrading enzymes such as endo- or exoamylases, pullulanases, debranching enzymes, hemicellulases including xylanases, cellulases, oxidoreductases, e.g. glucose oxidase, lipases, phospholipases and hexose oxidase, and proteases

20 The foodstuff according to the present invention may suitable comprise one or more of the following additives:

soy protein material; carotenoids, flavenoids, antioxidant and phytochemical (especially anthocyanonide, carotenoid, bioflavinoid, glutathione, catechin, isoflavone, lycopene, ginsenoside, pycnogenol, alkaloid, pygeum phytosterol, sulphoraphane,
25 resveretol, grape seed extract or food containing stanol esters), vitamin (especially vitamin C, vitamin A, vitamin B3, vitamin D, vitamin E, thiamine, riboflavin, niacin, pyridoxine, cyanocobalamin, folic acid, biotin, pantothenic acid or vitamin K), minerals (especially calcium, iodine, magnesium, zinc, iron, selenium, manganese, chromium, copper, cobalt, molybdenum or phosphorus), fatty acid (especially gamma-
30 linoleic acid, nicospentaenoic acid or decosahexaenoic acid), oil (especially borage oil, high carotenoid canola oil or flax seed oil), amino acid (especially tryptophan, lysine, methionine, phenylalanine, threonine, valine, leucine, isoleucine, alanine, arginine,

aspartic acid, cystine, cysteine, glutamic acid, glutamine, glycine, histidine, proline, hydroxyproline, serine, taurine or tyrosine), enzyme (especially bromelain, papain, amylase, cellulase or coenzyme Q), lignin, stanol ester or friendly bacteria (especially Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus bifidus, 5 Lactobacillus plantarum or Streptococcus faecium), folic acid, and soluble fibre.

TECHNICAL EFFECT

Surprisingly lipid:sterol acyltransferases have significant acyltransferase activity in 10 foodstuffs. This activity has surprising beneficial applications in methods of preparing foodstuffs.

The present invention may provide one or more of the following unexpected technical effects in egg products, particularly mayonnaise: an improved heat stability during 15 pasteurisation; improved organoleptic properties.

The present invention may provide one or more of the following unexpected technical effects in dough and/or baked products: an improved specific volume of either the dough or the baked products (for example of bread and/or of cake); an improved 20 dough stability; an improved crust score (for example a thinner and/or crispier bread crust), an improved crumb score (for example a more homogenous crumb distribution and/or a finer crumb structure and/or a softer crumb); an improved appearance (for example a smooth surface without blisters or holes or substantially without blisters or holes); a reduced staling; an enhanced softness; an improved odour; an improved taste.

25

Suitably, the present invention may provide one or more of the following unexpected technical effects in a foodstuff: an improved appearance, an improved mouthfeel, an improved stability, an improved taste, an improved softness, an improved resilience, an improved emulsification.

30

Suitably, the present invention may provide one or more of the following unexpected technical effects in dairy products, such as ice cream for example: an improved

mouthfeel (preferably a more creamy mouthfeel); an improved taste; an improved meltdown.

Suitably, the present invention may provide one or more of the following unexpected technical effects in egg or in egg products: improved stability of emulsion; thermal stability of emulsion; improved flavour; reduced mal-odour; improved thickening properties.

Suitably, the present invention may provide one or more of the following unexpected technical effects in cheese: a decrease in the oiling-off effect in cheese; an increase in cheese yield; an improvement in flavour; a reduced mal-odour; a reduced "soapy" taste.

The improvements observed with lipid:sterol acyltransferase according to the present invention are in comparison to when lipolytic enzymes without acyltransferase activity, such as triacylglycerol lipases and phospholipases, are used.

ADVANTAGES

- The generation of an emulsifier and a sterol/stanol ester *in situ* from at least one constituent of the food material, means that the food material will contain at least one less additive material. This is advantageous because of the improvement in the ease of production. For example, no further processing or addition of ingredients or addition of emulsifiers may be required. Moreover, the foodstuff may contain less "additives".
- The reduction or elimination of "additives" is desirable to consumers and inclusion of additives often must be declared to the consumer in the ingredients listing on the foodstuff. Thus, the present invention is further advantageous.

An advantage of the present invention is the production *in situ* of an emulsifier in a foodstuff without a detrimental increase in the free fatty acid content of the foodstuff.

In addition, when the lipid:sterol acyltransferase acts on a glycolipid it is possible to advantageously produce the emulsifier DGMG *in situ* without a detrimental increase in the free fatty acid content of the foodstuff. Thus, reducing detrimental effects attributed to an increase in free fatty acids, including but not limited to a reduction in
5 "soapy" taste in cheese, prevention of overdosing in dough and dough baked properties.

For some aspects, an advantage of the present invention is the reduction in free cholesterol levels in the foodstuff.

10

For other aspect, an advantage of the present invention is the increase in stanol and/or sterol esters in the foodstuff. Some sterol/stanol esters may be effective flavourants and/or texturisers. Thus, the present invention may not only results in the *in situ* production of an emulsifier in a foodstuff, but also the *in situ* production of a
15 flavourant and/or a texturiser. Some sterol/stanol esters are known to reduce blood serum cholesterol and/or low density lipoproteins when consumed in a foodstuff. Thus, the present invention may be used to prepare a foodstuff with increased levels of sterol esters and/or stanol esters.

20 Also advantageously the emulsification properties of the foodstuff are enhanced, leading to improved appearance and/or handling properties and/or structure without negative impact on taste.

In addition, advantageously the effect of "overdosing" observed when using lipases
25 *per se*, is effectively overcome by the addition of an enzyme in accordance with the present invention. This is due at least in part to the fact that free fatty acids are not produced or only produced to an insignificant degree when using the enzyme according to the present invention.

30 ISOLATED

In one aspect, preferably the polypeptide or protein for use in the present invention is in an isolated form. The term "isolated" means that the sequence is at least substantially free from at least one other component with which the sequence is naturally associated in nature and as found in nature.

5

PURIFIED

In one aspect, preferably the polypeptide or protein for use in the present invention is in a purified form. The term "purified" means that the sequence is in a relatively pure state – e.g. at least about 51% pure, or at least about 75%, or at least about 80%, or at least about 90% pure, or at least about 95% pure or at least about 98% pure.

CLONING A NUCLEOTIDE SEQUENCE ENCODING A POLYPEPTIDE ACCORDING TO THE PRESENT INVENTION

15

A nucleotide sequence encoding either a polypeptide which has the specific properties as defined herein or a polypeptide which is suitable for modification may be isolated from any cell or organism producing said polypeptide. Various methods are well known within the art for the isolation of nucleotide sequences.

20

For example, a genomic DNA and/or cDNA library may be constructed using chromosomal DNA or messenger RNA from the organism producing the polypeptide. If the amino acid sequence of the polypeptide is known, labelled oligonucleotide probes may be synthesised and used to identify polypeptide-encoding clones from the genomic library prepared from the organism. Alternatively, a labelled oligonucleotide probe containing sequences homologous to another known polypeptide gene could be used to identify polypeptide-encoding clones. In the latter case, hybridisation and washing conditions of lower stringency are used.

Alternatively, polypeptide-encoding clones could be identified by inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming enzyme-

negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing an enzyme inhibited by the polypeptide, thereby allowing clones expressing the polypeptide to be identified.

- 5 In a yet further alternative, the nucleotide sequence encoding the polypeptide may be prepared synthetically by established standard methods, e.g. the phosphoroamidite method described by Beucage S.L. *et al* (1981) Tetrahedron Letters 22, p 1859-1869, or the method described by Matthes *et al* (1984) EMBO J. 3, p 801-805. In the phosphoroamidite method, oligonucleotides are synthesised, e.g. in an automatic DNA
10 synthesiser, purified, annealed, ligated and cloned in appropriate vectors.

- The nucleotide sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin, or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate) in accordance with
15 standard techniques. Each ligated fragment corresponds to various parts of the entire nucleotide sequence. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or in Saiki R K *et al* (Science (1988) 239, pp 487-491).

20

NUCLEOTIDE SEQUENCES

- The present invention also encompasses nucleotide sequences encoding polypeptides having the specific properties as defined herein. The term "nucleotide sequence" as used
25 herein refers to an oligonucleotide sequence or polynucleotide sequence, and variant, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be of genomic or synthetic or recombinant origin, which may be double-stranded or single-stranded whether representing the sense or antisense strand.

- 30 The term "nucleotide sequence" in relation to the present invention includes genomic DNA, cDNA, synthetic DNA, and RNA. Preferably it means DNA, more preferably cDNA for the coding sequence.

In a preferred embodiment, the nucleotide sequence *per se* encoding a polypeptide having the specific properties as defined herein does not cover the native nucleotide sequence in its natural environment when it is linked to its naturally associated sequence(s) that is/are
5 also in its/their natural environment. For ease of reference, we shall call this preferred embodiment the "non-native nucleotide sequence". In this regard, the term "native nucleotide sequence" means an entire nucleotide sequence that is in its native environment and when operatively linked to an entire promoter with which it is naturally associated, which promoter is also in its native environment. Thus, the polypeptide of the
10 present invention can be expressed by a nucleotide sequence in its native organism but wherein the nucleotide sequence is not under the control of the promoter with which it is naturally associated within that organism.

Preferably the polypeptide is not a native polypeptide. In this regard, the term "native
15 polypeptide" means an entire polypeptide that is in its native environment and when it has been expressed by its native nucleotide sequence.

Typically, the nucleotide sequence encoding polypeptides having the specific properties as defined herein is prepared using recombinant DNA techniques (i.e.
20 recombinant DNA). However, in an alternative embodiment of the invention, the nucleotide sequence could be synthesised, in whole or in part, using chemical methods well known in the art (see Caruthers MH *et al* (1980) Nuc Acids Res Symp Ser 215-23 and Horn T *et al* (1980) Nuc Acids Res Symp Ser 225-232).

25 MOLECULAR EVOLUTION

Once an enzyme-encoding nucleotide sequence has been isolated, or a putative enzyme-encoding nucleotide sequence has been identified, it may be desirable to modify the selected nucleotide sequence, for example it may be desirable to mutate the
30 sequence in order to prepare an enzyme in accordance with the present invention.

Mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.

A suitable method is disclosed in Morinaga *et al* (Biotechnology (1984) 2, p646-649).

- 5 Another method of introducing mutations into enzyme-encoding nucleotide sequences is described in Nelson and Long (Analytical Biochemistry (1989), 180, p 147-151).

- 10 Instead of site directed mutagenesis, such as described above, one can introduce mutations randomly for instance using a commercial kit such as the GeneMorph PCR mutagenesis kit from Stratagene, or the Diversify PCR random mutagenesis kit from Clontech.

- 15 A third method to obtain novel sequences is to fragment non-identical nucleotide sequences, either by using any number of restriction enzymes or an enzyme such as Dnase I, and reassembling full nucleotide sequences coding for functional proteins. Alternatively one can use one or multiple non-identical nucleotide sequences and introduce mutations during the reassembly of the full nucleotide sequence.

- 20 Thus, it is possible to produce numerous site directed or random mutations into a nucleotide sequence, either *in vivo* or *in vitro*, and to subsequently screen for improved functionality of the encoded polypeptide by various means.

- 25 As a non-limiting example, In addition, mutations or natural variants of a polynucleotide sequence can be recombined with either the wildtype or other mutations or natural variants to produce new variants. Such new variants can also be screened for improved functionality of the encoded polypeptide.

- 30 The application of the above-mentioned and similar molecular evolution methods allows the identification and selection of variants of the enzymes of the present invention which have preferred characteristics without any prior knowledge of protein structure or function, and allows the production of non-predictable but beneficial mutations or variants. There are numerous examples of the application of molecular

- evolution in the art for the optimisation or alteration of enzyme activity, such examples include, but are not limited to one or more of the following: optimised expression and/or activity in a host cell or in vitro, increased enzymatic activity, altered substrate and/or product specificity, increased or decreased enzymatic or structural stability,
- 5 altered enzymatic activity/specificity in preferred environmental conditions, e.g. temperature, pH, substrate

AMINO ACID SEQUENCES

- 10 The present invention also encompasses amino acid sequences of polypeptides having the specific properties as defined herein.

- As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and/or the term "protein". In some instances, the term "amino acid
- 15 sequence" is synonymous with the term "peptide".

The amino acid sequence may be prepared/isolated from a suitable source, or it may be made synthetically or it may be prepared by use of recombinant DNA techniques.

- 20 Suitably, the amino acid sequences may be obtained from the isolated polypeptides taught herein by standard techniques.

One suitable method for determining amino acid sequences from isolated polypeptides is as follows:

25

Purified polypeptide may be freeze-dried and 100 µg of the freeze-dried material may be dissolved in 50 µl of a mixture of 8 M urea and 0.4 M ammonium hydrogen carbonate, pH 8.4. The dissolved protein may be denatured and reduced for 15 minutes at 50°C following overlay with nitrogen and addition of 5 µl of 45 mM dithiothreitol.

- 30 After cooling to room temperature, 5 µl of 100 mM iodoacetamide may be added for the cysteine residues to be derivatized for 15 minutes at room temperature in the dark under nitrogen.

135 μ l of water and 5 μ g of endoproteinase Lys-C in 5 μ l of water may be added to the above reaction mixture and the digestion may be carried out at 37°C under nitrogen for 24 hours.

5

The resulting peptides may be separated by reverse phase HPLC on a VYDAC C18 column (0.46x15cm;10 μ m; The Separation Group, California, USA) using solvent A: 0.1% TFA in water and solvent B: 0.1% TFA in acetonitrile. Selected peptides may be re-chromatographed on a Develosil C18 column using the same solvent system, prior to N-terminal sequencing. Sequencing may be done using an Applied Biosystems 476A sequencer using pulsed liquid fast cycles according to the manufacturer's instructions (Applied Biosystems, California, USA).

15 SEQUENCE IDENTITY OR SEQUENCE HOMOLOGY

The present invention also encompasses the use of sequences having a degree of sequence identity or sequence homology with amino acid sequence(s) of a polypeptide having the specific properties defined herein or of any nucleotide sequence encoding such a polypeptide (hereinafter referred to as a "homologous sequence(s)"). Here, the term "homologue" means an entity having a certain homology with the subject amino acid sequences and the subject nucleotide sequences. Here, the term "homology" can be equated with "identity".

25 The homologous amino acid sequence and/or nucleotide sequence should provide and/or encode a polypeptide which retains the functional activity and/or enhances the activity of the enzyme.

In the present context, a homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to the subject sequence. Typically, the homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be

considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

- 5 In the present context, a homologous sequence is taken to include a nucleotide sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical to a nucleotide sequence encoding a polypeptide of the present invention (the subject sequence). Typically, the homologues will comprise the same sequences that code for the active sites etc. as the subject sequence. Although homology can also be
10 considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

- Homology comparisons can be conducted by eye, or more usually, with the aid of
15 readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

- % homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly
20 compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

- Although this is a very simple and consistent method, it fails to take into consideration
25 that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and
30 deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (Devereux *et al* 1984 Nuc. Acids Research 12 p387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel *et al* 1999 Short Protocols in Molecular Biology, 4th Ed - Chapter 18), FASTA (Altschul *et al* 1990 J. Mol. Biol. 403-410) and the GENWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel *et al* 1999, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequence (see FEMS Microbiol Lett 1999 174(2): 247-50; FEMS Microbiol Lett 1999 177(1): 187-8 and tatiana@ncbi.nlm.nih.gov).

Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the

BLAST suite of programs. GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as

5 BLOSUM62.

Alternatively, percentage homologies may be calculated using the multiple alignment feature in DNASIS™ (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), *Gene* 73(1), 237-244).

10

Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

15 The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is

20 retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

25

Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

30

ALIPHATIC	Non-polar	G A P
-----------	-----------	-------

	Polar – uncharged	ILV
		CSTM
		NQ
	Polar – charged	DE
		KR
AROMATIC		HFVY

The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) that may occur i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc. Non-homologous substitution may also occur i.e. from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid, ornithine (hereinafter referred to as B), norleucine, ornithine (hereinafter referred to as O), pyriylalanine, thienylalanine, naphthylalanine and phenylglycine.

Replacements may also be made by unnatural amino acids.

Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or β -alanine residues. A further form of variation, involves the presence of one or more amino acid residues in peptoid form, will be well understood by those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid residues wherein the α -carbon substituent group is on the residue's nitrogen atom rather than the α -carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon RJ et al., PNAS (1992) 89(20), 9367-9371 and Horwell DC, Trends Biotechnol. (1995) 13(4), 132-134.

Nucleotide sequences for use in the present invention or encoding a polypeptide having the specific properties defined herein may include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate
5 backbones and/or the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the nucleotide sequences described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of nucleotide sequences.

10

The present invention also encompasses the use of nucleotide sequences that are complementary to the sequences discussed herein, or any derivative, fragment or derivative thereof. If the sequence is complementary to a fragment thereof then that sequence can be used as a probe to identify similar coding sequences in other
15 organisms etc.

Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other variants of the sequences described herein may be obtained for example by probing
20 DNA libraries made from a range of individuals, for example individuals from different populations. In addition, other viral/bacterial, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such
25 sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of any one of the sequences in the attached sequence listings under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of the polypeptide or nucleotide sequences of the
30 invention.

Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention. Conserved sequences can be predicted, for example, by aligning the amino acid
5 sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used.

The primers used in degenerate PCR will contain one or more degenerate positions and
10 will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised sequences. This may be useful where for example silent codon sequence
15 changes are required to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction polypeptide recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

20 Polynucleotides (nucleotide sequences) of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40
25 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.

Polynucleotides such as DNA polynucleotides and probes according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in
30 the art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

- 5 Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain
10 reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector.

15 HYBRIDISATION

- The present invention also encompasses sequences that are complementary to the sequences of the present invention or sequences that are capable of hybridising either to the sequences of the present invention or to sequences that are complementary
20 thereto.

- The term "hybridisation" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction (PCR)
25 technologies.

- The present invention also encompasses the use of nucleotide sequences that are capable of hybridising to the sequences that are complementary to the subject sequences discussed herein, or any derivative, fragment or derivative thereof.

30

The present invention also encompasses sequences that are complementary to sequences that are capable of hybridising to the nucleotide sequences discussed herein.

5 Hybridisation conditions are based on the melting temperature (T_m) of the nucleotide binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol. 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.

10 Maximum stringency typically occurs at about $T_m - 5^\circ\text{C}$ (5°C below the T_m of the probe); high stringency at about 5°C to 10°C below T_m ; intermediate stringency at about 10°C to 20°C below T_m ; and low stringency at about 20°C to 25°C below T_m . As will be understood by those of skill in the art, a maximum stringency hybridisation can be used to identify or detect identical nucleotide sequences while an intermediate (or low) stringency hybridisation can be used to identify or detect similar or related polynucleotide sequences.

15 Preferably, the present invention encompasses sequences that are complementary to sequences that are capable of hybridising under high stringency conditions or intermediate stringency conditions to nucleotide sequences encoding polypeptides having the specific properties as defined herein.

25 More preferably, the present invention encompasses sequences that are complementary to sequences that are capable of hybridising under high stringent conditions (e.g. 65°C and $0.1\times\text{SSC}$ ($1\times\text{SSC} = 0.15\text{ M NaCl}$, $0.015\text{ M Na-citrate pH } 7.0$)) to nucleotide sequences encoding polypeptides having the specific properties as defined herein.

The present invention also relates to nucleotide sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).

30

The present invention also relates to nucleotide sequences that are complementary to sequences that can hybridise to the nucleotide sequences discussed herein (including complementary sequences of those discussed herein).

- 5 Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridising to the nucleotide sequences discussed herein under conditions of intermediate to maximal stringency.

In a preferred aspect, the present invention covers nucleotide sequences that can
10 hybridise to the nucleotide sequences discussed herein, or the complement thereof, under stringent conditions (e.g. 50°C and 0.2xSSC).

In a more preferred aspect, the present invention covers nucleotide sequences that can
15 hybridise to the nucleotide sequences discussed herein, or the complement thereof, under high stringent conditions (e.g. 65°C and 0.1xSSC).

EXPRESSION OF POLYPEPTIDES

A nucleotide sequence for use in the present invention or for encoding a polypeptide
20 having the specific properties as defined herein can be incorporated into a recombinant replicable vector. The vector may be used to replicate and express the nucleotide sequence, in polypeptide form, in and/or from a compatible host cell. Expression may be controlled using control sequences which include promoters/enhancers and other expression regulation signals. Prokaryotic promoters and promoters functional in
25 eukaryotic cells may be used. Tissue specific or stimuli specific promoters may be used. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.

The polypeptide produced by a host recombinant cell by expression of the nucleotide
30 sequence may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. The coding sequences can be designed with signal

sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane.

EXPRESSION VECTOR

5

The term "expression vector" means a construct capable of *in vivo* or *in vitro* expression.

Preferably, the expression vector is incorporated in the genome of the organism. The term "incorporated" preferably covers stable incorporation into the genome.

10

The nucleotide sequence of the present invention or coding for a polypeptide having the specific properties as defined herein may be present in a vector, in which the nucleotide sequence is operably linked to regulatory sequences such that the regulatory sequences are capable of providing the expression of the nucleotide sequence by a suitable host organism, i.e. the vector is an expression vector.

15

The vectors of the present invention may be transformed into a suitable host cell as described below to provide for expression of a polypeptide having the specific properties as defined herein.

20

The choice of vector, e.g. plasmid, cosmid, virus or phage vector, will often depend on the host cell into which it is to be introduced.

25

The vectors may contain one or more selectable marker genes – such as a gene which confers antibiotic resistance e.g. ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Alternatively, the selection may be accomplished by co-transformation (as described in WO91/17243).

30

Vectors may be used *in vitro*, for example for the production of RNA or used to transfect or transform a host cell.

Thus, in a further embodiment, the invention provides a method of making nucleotide sequences of the present invention or nucleotide sequences encoding polypeptides having the specific properties as defined herein by introducing a nucleotide sequence into a replicable vector, introducing the vector into a compatible host cell, and growing
5 the host cell under conditions which bring about replication of the vector.

The vector may further comprise a nucleotide sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.
10

REGULATORY SEQUENCES

15 In some applications, a nucleotide sequence for use in the present invention or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein may be operably linked to a regulatory sequence which is capable of providing for the expression of the nucleotide sequence, such as by the chosen host cell. By way
20 of example, the present invention covers a vector comprising the nucleotide sequence of the present invention operably linked to such a regulatory sequence, i.e. the vector is an expression vector.

The term "operably linked" refers to a juxtaposition wherein the components described
25 are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

30 The term "regulatory sequences" includes promoters and enhancers and other expression regulation signals.

The term "promoter" is used in the normal sense of the art, e.g. an RNA polymerase binding site.

Enhanced expression of the nucleotide sequence encoding the enzyme having the specific properties as defined herein may also be achieved by the selection of heterologous regulatory regions, e.g. promoter, secretion leader and terminator regions.

Preferably, the nucleotide sequence of the present invention may be operably linked to at least a promoter.

Examples of suitable promoters for directing the transcription of the nucleotide sequence in a bacterial, fungal or yeast host are well known in the art.

CONSTRUCTS

The term "construct" - which is synonymous with terms such as "conjugate", "cassette" and "hybrid" - includes a nucleotide sequence encoding a polypeptide having the specific properties as defined herein for use according to the present invention directly or indirectly attached to a promoter. An example of an indirect attachment is the provision of a suitable spacer group such as an intron sequence, such as the Sh1-intron or the ADH intron, intermediate the promoter and the nucleotide sequence of the present invention. The same is true for the term "fused" in relation to the present invention which includes direct or indirect attachment. In some cases, the terms do not cover the natural combination of the nucleotide sequence coding for the protein ordinarily associated with the wild type gene promoter and when they are both in their natural environment.

The construct may even contain or express a marker which allows for the selection of the genetic construct.

For some applications, preferably the construct comprises at least a nucleotide sequence of the present invention or a nucleotide sequence encoding a polypeptide having the specific properties as defined herein operably linked to a promoter.

5 HOST CELLS

The term "host cell" - in relation to the present invention includes any cell that comprises either a nucleotide sequence encoding a polypeptide having the specific properties as defined herein or an expression vector as described above and which is
10 used in the recombinant production of a polypeptide having the specific properties as defined herein.

Thus, a further embodiment of the present invention provides host cells transformed or transfected with a nucleotide sequence of the present invention or a nucleotide
15 sequence that expresses a polypeptide having the specific properties as defined herein. The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells. Preferably, the host cells are not human cells.

20 Examples of suitable bacterial host organisms are gram negative bacterium or gram positive bacteria.

Depending on the nature of the nucleotide sequence encoding a polypeptide having the specific properties as defined herein, and/or the desirability for further processing of
25 the expressed protein, eukaryotic hosts such as yeasts or other fungi may be preferred. In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a different fungal host organism should be selected.

30

The use of suitable host cells, such as yeast, fungal and plant host cells - may provide for post-translational modifications (e.g. myristoylation, glycosylation, truncation,

lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.

- 5 The host cell may be a protease deficient or protease minus strain.

ORGANISM

- 10 The term "organism" in relation to the present invention includes any organism that could comprise a nucleotide sequence according to the present invention or a nucleotide sequence encoding for a polypeptide having the specific properties as defined herein and/or products obtained therefrom.

Suitable organisms may include a prokaryote, fungus, yeast or a plant.

15

- The term "transgenic organism" in relation to the present invention includes any organism that comprises a nucleotide sequence coding for a polypeptide having the specific properties as defined herein and/or the products obtained therefrom, and/or wherein a promoter can allow expression of the nucleotide sequence coding for a polypeptide having the specific properties as defined herein within the organism. Preferably the nucleotide sequence is incorporated in the genome of the organism.
- 20

- The term "transgenic organism" does not cover native nucleotide coding sequences in their natural environment when they are under the control of their native promoter which is also in its natural environment.
- 25

- Therefore, the transgenic organism of the present invention includes an organism comprising any one of, or combinations of, a nucleotide sequence coding for a polypeptide having the specific properties as defined herein, constructs as defined herein, vectors as defined herein, plasmids as defined herein, cells as defined herein, or the products thereof. For example the transgenic organism can also comprise a
- 30

nucleotide sequence coding for a polypeptide having the specific properties as defined herein under the control of a heterologous promoter.

TRANSFORMATION OF HOST CELLS/ORGANISM

5

As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include *E. coli* and *Bacillus subtilis*.

10 Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook *et al* (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press). If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as by removal of introns.

15 In another embodiment the transgenic organism can be a yeast.

Filamentous fungi cells may be transformed using various methods known in the art - such as a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a manner known. The use of *Aspergillus*
20 as a host microorganism is described in EP 0 238 023.

Another host organism can be a plant. A review of the general techniques used for transforming plants may be found in articles by Potrykus (*Annu Rev Plant Physiol Plant Mol Biol* [1991] 42:205-225) and Christou (*Agro-Food-Industry Hi-Tech*
25 March/April 1994 17-27). Further teachings on plant transformation may be found in EP-A-0449375.

General teachings on the transformation of fungi, yeasts and plants are presented in following sections.

30

TRANSFORMED FUNGUS

A host organism may be a fungus - such as a filamentous fungus. Examples of suitable such hosts include any member belonging to the genera *Thermomyces*, *Acremonium*,
 5 *Aspergillus*, *Penicillium*, *Mucor*, *Neurospora*, *Trichoderma* and the like.

Teachings on transforming filamentous fungi are reviewed in US-A-5741665 which states that standard techniques for transformation of filamentous fungi and culturing the fungi are well known in the art. An extensive review of techniques as applied to *N.*
 10 *crassa* is found, for example in Davis and de Serres, *Methods Enzymol* (1971) 17A: 79-143.

Further teachings on transforming filamentous fungi are reviewed in US-A-5674707.

15 In one aspect, the host organism can be of the genus *Aspergillus*, such as *Aspergillus niger*.

A transgenic *Aspergillus* according to the present invention can also be prepared by following, for example, the teachings of Turner G. 1994 (Vectors for genetic
 20 manipulation. In: Martinelli S.D., Kinghorn J.R. (Editors) *Aspergillus*: 50 years on. Progress in industrial microbiology vol 29. Elsevier Amsterdam 1994. pp. 641-666).

Gene expression in filamentous fungi has been reviewed in Punt *et al.* (2002) Trends Biotechnol 2002 May;20(5):200-6, Archer & Peberdy Crit Rev Biotechnol (1997)
 25 17(4):273-306.

TRANSFORMED YEAST

In another embodiment, the transgenic organism can be a yeast.

30

A review of the principles of heterologous gene expression in yeast are provided in, for example, *Methods Mol Biol* (1995), 49:341-54, and *Curr Opin Biotechnol* (1997) Oct;8(5):554-60

- 5 In this regard, yeast – such as the species *Saccharomyces cerevisiae* or *Pichia pastoris* (see FEMS Microbiol Rev (2000 24(1):45-66), may be used as a vehicle for heterologous gene expression.

- 10 A review of the principles of heterologous gene expression in *Saccharomyces cerevisiae* and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a vehicle for the expression of heterologous genes", *Yeasts*, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

- For the transformation of yeast, several transformation protocols have been developed.
- 15 For example, a transgenic *Saccharomyces* according to the present invention can be prepared by following the teachings of Hinnen *et al.*, (1978, *Proceedings of the National Academy of Sciences of the USA* 75, 1929); Beggs, J D (1978, *Nature*, London, 275, 104); and Ito, H *et al* (1983, *J Bacteriology* 153, 163-168).
- 20 The transformed yeast cells may be selected using various selective markers – such as auxotrophic markers dominant antibiotic resistance markers.

TRANSFORMED PLANTS/PLANT CELLS

- 25 A host organism suitable for the present invention may be a plant. A review of the general techniques may be found in articles by Potrykus (*Annu Rev Plant Physiol Plant Mol Biol* [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27).

- 30 SECRETION

Often, it is desirable for the polypeptide to be secreted from the expression host into the culture medium from where the enzyme may be more easily recovered. According to the present invention, the secretion leader sequence may be selected on the basis of the desired expression host. Hybrid signal sequences may also be used with the
5 context of the present invention.

Typical examples of heterologous secretion leader sequences are those originating from the fungal amyloglucosidase (AG) gene (*glaA* - both 18 and 24 amino acid versions e.g. from *Aspergillus*), the α -factor gene (yeasts e.g. *Saccharomyces*,
10 *Kluyveromyces* and *Hansenula*) or the α -amylase gene (*Bacillus*).

DETECTION

A variety of protocols for detecting and measuring the expression of the amino acid
15 sequence are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS).

A wide variety of labels and conjugation techniques are known by those skilled in the
20 art and can be used in various nucleic and amino acid assays.

A number of companies such as Pharmacia Biotech (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for these procedures.
25

Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US-A-3,817,837; US-A-3,850,752; US-A-3,939,350; US-A-3,996,345; US-A-
30 4,277,437; US-A-4,275,149 and US-A-4,366,241.

Also, recombinant immunoglobulins may be produced as shown in US-A-4,816,567.

FUSION PROTEINS

- A polypeptide having the specific properties as defined herein may be produced as a fusion protein, for example to aid in extraction and purification thereof. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and β -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the activity of the protein sequence.

Gene fusion expression systems in *E. coli* have been reviewed in Curr. Opin. Biotechnol. (1995) 6(5):501-6.

- In another embodiment of the invention, the amino acid sequence of a polypeptide having the specific properties as defined herein may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a heterologous epitope that is recognised by a commercially available antibody.

The invention will now be described, by way of example only, with reference to the following Figures and Examples.

- Figure 1 shows a pfam00657.6 consensus sequence (SEQ ID No. 1);

Figure 2 shows an amino acid sequence (SEQ ID No. 2) obtained from the organism *Aeromonas hydrophila*;

- Figure 3 shows an amino acid sequence (SEQ ID No. 3) obtained from the organism *Aeromonas salmonicida*;

Figure 4 shows an amino acid sequence (SEQ ID No. 4) obtained from the organism *Streptomyces coelicolor* A3(2) (Genbank accession number NP_631558);

Figure 5 shows an amino acid sequence (SEQ ID No. 5) obtained from the organism
5 *Streptomyces coelicolor* A3(2) (Genbank accession number: CAC42140);

Figure 6 shows an amino acid sequence (SEQ ID No. 6) obtained from the organism *Saccharomyces cerevisiae* (Genbank accession number P41734);

10 Figure 7 shows an alignment of selected sequences to pfam00657.6 consensus sequence;

Figure 8 shows a pairwise alignment of SEQ ID No. 3 with SEQ ID No. 2 showing 93% amino acid sequence identity. The signal sequence is underlined. + denotes
15 differences. The GDSX motif containing the active site serine 16, and the active sites aspartic acid 116 and histidine 291 are highlighted (see shaded regions). Numbers after the amino acid is minus the signal sequence;

Figure 9 shows a nucleotide sequence (SEQ ID No. 7) encoding a lipid:sterol acyl
20 transferase according to the present invention obtained from the organism *Aeromonas hydrophila*;

Figure 10 shows a nucleotide sequence (SEQ ID No. 8) encoding a lipid:sterol acyl
25 transferase according to the present invention obtained from the organism *Aeromonas salmonicida*;

Figure 11 shows a nucleotide sequence (SEQ ID No. 9) encoding a lipid:sterol acyl transferase according to the present invention obtained from the organism *Streptomyces coelicolor* A3(2) (Genbank accession number
30 NC_003888.1:8327480..8328367);

Figure 12 shows a nucleotide sequence (SEQ ID No. 10) encoding a lipid:sterol acyl transferase according to the present invention obtained from the organism *Streptomyces coelicolor* A3(2) (Genbank accession number AL939131.1:265480..266367);

5

Figure 13 shows a nucleotide sequence (SEQ ID No. 11) encoding a lipid:sterol acyl transferase according to the present invention obtained from the organism *Saccharomyces cerevisiae* (Genbank accession number Z75034);

10 Figure 14 shows an amino acid sequence (SEQ ID No. 12) obtained from the organism *Ralstonia* (Genbank accession number: AL646052);

Figure 15 shows a nucleotide sequence (SEQ ID No. 13) encoding a lipid:sterol acyl transferase according to the present invention obtained from the organism *Ralstonia*;

15 and

Figure 16 shows that homologues of the *Aeromonas* genes can be identified using the basic local alignment search tool service at the National Center for Biotechnology Information, NIH, MD, USA and the completed genome databases. The GDSX motif was used in the database search and a number of sequences/genes potentially encoding enzymes with lipolytic activity were identified. Genes were identified from the genus *Streptomyces*, *Xanthomonas* and *Ralstonia*. As an example below, the *Ralstonia solanacearum* was aligned to the *Aeromonas salmonicida* (satA) gene. Pairwise alignment showed 23% identity. The active site serine is present at the amino terminus and the catalytic residues histidine and aspartic acid can be identified.

25

EXAMPLES

EXAMPLE 1: Use of lipid:sterol acyltransferase for mayonnaise production.

30

The lecithin content of egg yolk is an important emulsifier for the production of mayonnaise with the limitation that the mayonnaise is not heat stable. It has therefore

been known for several years to use a phospholipase from pancreas to modify lecithin in egg yolk to lysolecithin, which is a more efficient emulsifier. The use of enzyme modified egg yolk in mayonnaise production contributes to better heat stability of the mayonnaise during pasteurisation. A limitation of using pancreas phospholipase in egg yolk is that the amount of free fatty acid also increases, which contributes to reduced oxidative stability because free fatty acids are more prone to oxidation than the corresponding ester. Free fatty acid may also contribute to a soapy off taste.

In accordance with the present invention it has now been shown that it is possible to produce lysolecithin from egg yolk without free fatty acid formation by use of a lipid:sterol acyltransferase.

In the following experiment a lipid:sterol acyltransferase is used for the production of mayonnaise according to the following procedure.

Ingredient	Negative Control (without enzyme)	Positive Control (with phospholipase A2 enzyme)	With lipid:sterol acyltransferase
	%	%	%
Vegetable oil	50	50	50
Egg yolk	5	5	5
Starch	2	2	2
Dextrose	1.0	1.0	1.0
Salt	0.75	0.75	0.75
Preserving agents	0.1	0.1	0.1
Vinegar	3.5	3.5	3.5
Mustard	2	2	2
Water	35.65	35.55	35.55
Lipid:sterol acyltransferase 500 LATU(St)/g			0.1

Pancreas Phospholipase A2 (200PLU/g)		0.5	
---	--	-----	--

Procedure:

The egg yolk, dextrose and lipid:sterol acyltransferase or pancreatic phospholipase A2 (if any) are transferred to a mixing bowl and agitated at 30°C for 20 minutes. All of the
 5 other ingredients are then mixed and emulsified in a batch mixing process. After mixing the mayonnaise is pasteurised at 95°C for 5 minutes.

The stability of the mayonnaise is evaluated by measuring the oil droplet size using a Malvern mastersizer. The oil droplet size of the mayonnaise prepared with the enzyme
 10 is significantly smaller than the oil droplet size of the mayonnaise prepared without the enzyme (i.e. the control mayonnaise).

A sample of the control egg yolk and the enzyme treated egg yolk is extracted with $\text{CHCl}_3:\text{CH}_3\text{OH}$ 2:1 and the organic solvent phase is isolated and analysed by HPLC
 15 and GLC for the following compounds: phosphatidylcholine (PC), lysophosphatidylcholine (LPC), free fatty acids, free cholesterol, cholesterol esters.

Results and conclusion:

20 Preliminary results of oil droplet size after pasteurisation of the mayonnaise indicate that the enzyme treatment of the egg yolk facilitates better emulsification stability of the mayonnaise as compared with the control mayonnaise with no enzyme and the positive control mayonnaise with phospholipase A2.

25 Preliminary results of the HPLC and GLC analyses indicate that the amount of PC in the "enzyme treated" mayonnaise is reduced as compared with the control mayonnaise, whilst the amount of LPC is increase in the enzyme treated mayonnaise as compared with the control mayonnaise. The increase in the amount of LPC may well explain the improved emulsification properties of the enzyme treated mayonnaise
 30 as compared with the control mayonnaise. The HPLC and GLC analyses also indicate

a lower level of free cholesterol in the enzyme treated mayonnaise as compared with the control mayonnaise, probably due to the cholesterol being used as an acceptor molecule in the transferase reaction resulting in an increase in the amount of cholesterol esters in the enzyme treated mayonnaise as compared with the control
 5 mayonnaise. In addition, preliminary results indicate that the amount of free fatty acids do not increases significantly when egg yolk is treated with lipid:sterol acyltransferase. Preliminary results further indicate that the amount of free fatty acids produced in the foodstuff treated with the lipid:sterol acyltransferase is significantly lower than in the foodstuff treated with the pancreatic phospholipase, this is true even
 10 if the amount of lysolecithin formed in the foodstuffs is the same.

EXAMPLE 2: Use of lipid:sterol acyltransferase for production of sponge cake.

Emulsifiers are widely used to improve the cake batter aeration in industrial
 15 production of sponge cake, and especially in the 'all-in' procedure the emulsifiers are essential in order to obtain good aeration which contributes to improved batter stability and a sponge cake with good volume and nice homogenous crumb structure.

In this example, a lipid:sterol acyltransferase is tested in a sponge cake recipe and
 20 compared with a high quality cake emulsifier Gatodan 504.

Sponge cake recipe:

	1	2	3
Ingredients	Negative Control*	Positive control: Commercial Emulsifier	Enzyme
Sugar	168	168	168
Dextrose	40	40	40
Soya oil	40	40	40
Egg	200	200	200
Corn starch	60	60	60

Wheat starch	188	188	188
Flour	188	188	188
Water	110	110	110
Gatodan 504 cake gel**		15	
Lipid acyl transferase, 500 LATU(St)/g			2
Baking powder	14	14	14
Flavouring	3	3	3

* Negative control means no enzyme and no commercial emulsifier

**Gatodan 504 cake gel is a cake improver containing monoglyceride and propyleneglycolester

5 Procedure:

Egg, oil and dextrose are transferred to a mixing bowl. Lipid:sterol acyltransferase or emulsifier (if any) is added and the mixture is agitated for 10 minutes.

Mixing: The other ingredients are added and the cake batter is mixed on a Hobart Mixer for 2 minutes in 1st gear and for 3 minutes in 3rd gear.

10 Baking:

350 g cake batter is scaled in a cake tin and baked at 180 °C for approx. 35 min.

After baking the cakes are cooled to ambient temperature and specific cake volume(ml/g) is measured. Cake appearance and crumb structure is evaluated subjectively.

15

After baking a part of the cake crumb is frozen and freeze-dried. The freeze-dried cake crumb is ground in a mill, sieved and extracted with CHCl_3 : CH_3OH 2:1

Emulsifiers in the lipid phase are analysed by HPLC and GLC.

20

Results and conclusion:

Preliminary results indicate that use of the lipid:sterol acyl transferase in sponge cake results in sponge cake with significantly improved cake quality and appearance as compared with the negative control. In particular, the cakes produced with the enzyme

have a better specific volume, a better appearance (i.e. a smoother surface with less blisters and/or holes and a taller cake), and a better crumb structure (i.e. more homogenous and/or a more tender crumb) as compared with the negative control. The results achieved were almost comparable with those obtained using the conventional cake improver (Gatodan 504).

Preliminary results further indicate that the amounts of monoglyceride and lysolecithin were increased in cakes produced using the enzyme as compared with the negative control.

10

Preliminary results also indicate that the amount of free cholesterol (typically from the egg yolk) is reduced in the cakes treated with the enzyme as compared with the positive and negative controls. This is because the enzyme uses cholesterol as an acceptor molecule during the transferase reaction.

15

EXAMPLE 3: Bread with lipid-sterol acyltransferase

Lipase and phospholipases have been used for more than a decade in the baking industry for the improvement of baking performance of flour when used in bread making. When added to a dough lipases are able to modify the endogenous and added lipid during production of more polar lipid, which facilitate better emulsification and stabilisation of the dough and contribute to produce a bread with better shape and volume as well as improved crumb structure.

One of the limitations of using lipase in bread making is that not only polar lipids are produced, but free fatty acid is also formed during the lipase reaction. It is well known that formation of too much free fatty acid will have a negative impact on the baking performance of flour, because the gluten gets too stiff and a bucky dough is formed which can not expand during fermentation and baking.

30

Formation of free fatty acid should also be prevented from the point of oxidative stability, because free fatty acids are more prone to lipid oxidation than the corresponding triacylglyceride.

- 5 Another limitation of using phospholipase and galactolipase in a dough is that the amount of lysolecithin and galactosylmonoesters produced is limited to the amount of available substrate (DGDG and lecithin) in the dough.

- 10 In the following experiments lipid:sterol acyltransferase is tested in mini scale baking experiments, and the lipid components in fully proved dough were extracted by water saturated butanol and analysed by HPLC and GLC analysis.

Materials and methods:

- 15 Enzymes:

Lipid:sterol acyltransferase, 550 LATU(St)/g

Grindamyl Exel 16 (Danisco A/S, Denmark) 5000LIPU/g

Flour : Sølvmeel nr. 2001084

- 20

Mini baking test:

Flour 50 gram, dry yeast 1.0 gram, glucose 0.8 gram, salt 0.8 gram, 50 ppm ascorbic acid, enzyme (either lipid:sterol acyltransferase or Grindamyl Exel 16) (if any), water 400 Brabender units is kneaded in a 50 g Brabender mixing bowl for 5 min at 30 °C.

- 25 Resting time is 10 min. at 34°C . The dough is scaled 15 gram per dough. Then moulded on a special device where the dough is rolled between a wooden plate and a plexiglas frame. The dough's were proofed in tins for 45 min. at 34 °C, and baked in a Voss household oven 8 min, 225 °C.

- 30 After baking the breads are cooled to ambient temperature and after 20 min. the breads are scaled and the volume is determined by rape seed displacement method. The breads are also cut and crumb and crust evaluated.

- Lipid extraction and fatty acid analyses: 10 g of fully proofed dough is immediately frozen and freeze-dried. The freeze-dried dough is milled in a coffee mill and passed through a 800 micron screen. 1.5 g of freeze-dried dough is scaled in a 15 ml centrifuge tube with a screw lid. 7.5 ml water saturated butanol (WSB) is added. The centrifuge tube is placed in a boiling water bath for 10 minutes. The tubes are placed in a Rotamix and spun at 45 rpm for 20 min. at ambient temperature. Then place in boiling water bath again for 10 min. and turn on the Rotamix for 30 min. at ambient temperature. The tubes are centrifuged at 3500 g for 5 minutes. 5 ml supernatant is transferred into a vial. WSB is evaporated to dryness under a stream of nitrogen.

10

HPLC analysis:

Column: LiChrospher 100 DIOL 5 μ m (Merck art.16152) 250 x 4.0 mm id
with water jacket 50 °C.

- 15 Mobil phase: A:heptan/isopropanol/butanol/tetrahydrofuran/isooctan/H₂O*
64.5/17.5/7/5/5/1

B: isopropanol/butanol/tetrahydrofuran/isooctan/H₂O*
730/7/5/5/10

*1mmol trifluoro acetic acid /l mobile phase

- 20 (pH=6.6 adjusted with NH₃)

Pump: Waters 510 + Gradient controller.

<u>Gradient:</u>	Flow: ml/min	Time: min	%A	%B
	1.0	0	100	0
	1.0	25	0	100
	1.0	30	0	100
	1.0	35	100	0
	1.0	40	100	0

25

Detector: CUNOW DDL21 (evaporative light-scattering)
temp: 100 C. - volt:600 - air flow: 6.0 l/min

Injector: Hewlett Packard 1050. Injection volume: 50 μ l

Sample preparation:

The wheat lipid is dissolved in 5ml CHCl_3 - CH_3OH (75-25)
(sonicated for 10 min.) and filtered through 0.45m.

Calculation: Calibration curve for PC (lecithin standard from ILPS**) is used

to calculate the amount of glycolipids and phospholipids.

**International Lecithin and Phospholipid Society

Reference: Arnoldsson, K.C./ Kaufmann, P.

Chromatographia Vol.38,5/6-1994, 317-324

Gas Chromatography:

Perkin Elmer 8420 Capillary Gas Chromatography equipped with WCOT fused silica column 12.5 m x 0.25 mm ID x 0.1 μm 5%phenyl-methyl-silicone (CP Sil 8 CB from Crompack).

Carrier: Helium.

Injection: 1.5 μl with split.

Detector: FID. 385 °C.

Oven program:	1	2	3	4
Oven temperature, °C.	80	200	240	360
Isothermal, time, min	2	0	0	10
Temperature rate, °C. /min	20	10	12	

Sample preparation: 50 mg of wheat lipid is dissolved in 12ml heptane: pyridine 2:1 containing an internal standard heptadecane, 2 mg/ml. 500 μl of the sample is transferred to a crimp vial. 100 μl MSTFA(N-Methyl-N-trimethylsilyl-trifluoroacetamid) is added and the reaction incubated for 15 minutes at 90 °C.

Calculation: Response factors for mono-di-triglycerides and free fatty acid were determined from reference mixtures of these components. Based on these response factors the mono-di-triglycerides and free fatty acids in wheat lipids were calculated.

Lipase assay based on tributyrin as substrate (LIPU):

Lipase activity based on tributyrin is measured according to Food Chemical Codex, Forth Edition, National Academy Press, 1996, p 803. With the modification that the sample is dissolved in deionized water in stead of glycine buffer, and the pH stat set point is 5.5 instead of 7.

1 LIPU is defined as the quantity of enzyme which can liberate 1 μmol butyric acid per min. under assay conditions.

Lipid acyl transferase unit, LATU(St):

- 10 Lipid acyl transferase activity is defined as the amount of μmol cholesterol ester formed per minute from lecithin as donor and cholesterol as acceptor molecule under assay conditions.

Procedure:

- Substrate: 0.6% Avanti phospholipid(95%PC),0.4 % cholesterol(Sigma, 3137), 0.05M HEPES buffer pH 7, 5 mM CaCl_2 . Phospholipid and cholesterol are dispersed in the buffer by heating to 40 °C and homogenized on a Turrax mixer for 10 seconds. 1 ml substrate is thermostated to 30 °C for 5 minutes. 100 μl enzyme solution is added. After 10 minutes the reaction is stopped by adding 0.1 ml 1M HCl. The lipid components are extracted into an organic phase by adding 1 ml $\text{CHCl}_3:\text{CH}_3\text{OH}$ 2:1.
- 20 500 μl of the organic phase is transferred to a 10 ml flask and evaporated at 60 °C in a stream of nitrogen. The amount of cholesterol ester formed is determined by GLC analyses. Cholesterol ester is determined by GLC as mentioned below using cholesterol oleate as standard.

- 25 Experiments:

Baking experiments were conducted according the Mini baking test procedure with the addition of enzymes as shown in table 1.

- 30 Table 1

Experiment	Enzyme	Dosage per kg
------------	--------	---------------

		flour
1	Negative Control (no enzyme)	
2	Lipid:sterol acyltransferase	400 LATU(St)
3	Grindamyl Exel 16 (Positive control – lipolytic enzyme)	500 LIPU

Preliminary results show that bread baked with the lipid:sterol acyltransferase is significantly better than the negative control bread baked without enzyme addition in terms of improved bread volume and crumb structure. The bread baked with
5 lipid:sterol acyltransferase is even better than the bread baked with Grindamyl Exel 16.

Fully proofed dough from this baking experiment is frozen and freeze-dried and the dough lipid extracted with water saturated butanol(WSB). The isolated dough lipids are analysed by GLC and HPLC. Preliminary results of the HPLC analyses indicate
10 that the amount of DGDG decreased and the amount of DGMG increased in the bread from dough treated with lipid:sterol acyltransferase and with Grindamyl Exel 16.

Conclusions:

15 Preliminary experiments conducted with the lipid:sterol acyltransferase clearly demonstrate a positive effect on both bread volume and bread appearance. The lipid analyses confirms the transfer reaction of lipid in the dough as it is observed the amount of free fatty acid only marginally increases although the polar lipids DGDG and phosphatidylcholine (PC) are converted to the corresponding monoesters DGMG
20 and lysophosphatidylcholine (LPC).

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the present invention will be apparent to those skilled in the art without departing from the scope and

spirit of the present invention. Although the present invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are
5 obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims.

CLAIMS

1. A method for the *in situ* production of an emulsifier in a foodstuff, wherein the method is such that the emulsifier is produced without increasing or substantially without increasing the free fatty acids in the foodstuff, and
5 wherein the method comprises the step of adding a lipid:sterol acyltransferase to the foodstuff.
2. A method according to claim 1 wherein either a sterol ester or a stanol ester is also produced *in situ* in the foodstuff.
3. A method according to claim 1 or claim 2 wherein a second emulsifier is also
10 produced *in situ* in the foodstuff.
4. A method according to claim 2 wherein the sterol ester is one or more of alpha-sitosterol ester, beta-sitosterol ester, stigmasterol ester, ergosterol ester, campesterol ester or cholesterol ester.
5. A method according to claim 2 wherein the stanol ester is one or more beta-sitostanol or ss-sitostanol.
15
6. A method according to any one of the preceding claims wherein the lipid:sterol acyltransferase is characterised as an enzyme which possesses acyl transferase activity and which comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.
20
7. A method according to any one of the preceding claims wherein the lipid:sterol acyltransferase enzyme comprises H-309 or comprises a histidine residue at a position corresponding to His-309 in the amino acid sequence of the *Aeromonas hydrophila* lipolytic enzyme shown as SEQ ID No. 2.
- 25 8. A method according to any one of the preceding claims wherein the lipid:sterol acyltransferase is obtainable from an organism from one or more of the following genera: *Aeromonas*, *Streptomyces*, *Saccharomyces*, *Lactococcus*, *Mycobacterium*, *Streptococcus*, *Lactobacillus*, *Desulfotobacterium*, *Bacillus*, *Campylobacter*, *Vibrionaceae*, *Xylella*, *Sulfolobus*, *Aspergillus*,
30 *Schizosaccharomyces*, *Listeria*, *Neisseria*, *Mesorhizobium*, *Ralstonia*, *Xanthomonas* and *Candida*.

9. A method according to any one of the preceding claims wherein the lipid:sterol acyltransferase comprises one or more of the following amino acid sequences: (i) the amino acid sequence shown as SEQ ID No. 2; (ii) the amino acid sequence shown as SEQ ID No. 3; (iii) the amino acid sequence shown as SEQ ID No. 4; (iv) the amino acid sequence shown as SED ID No. 5; (v) the amino acid sequence shown as SEQ ID No. 6; (vi) the amino acid sequence shown as SEQ ID No. 12; (vii) an amino acid sequence which has 75% or more identity with any one of the sequences shown as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6 or SEQ ID No. 12.
10. A method according to any one of the preceding claims, wherein the emulsifier is one or more of the following: a monoglyceride or a lysophosphatidylcholine.
11. Use of a lipid:sterol acyltransferase to prepare from a food material a foodstuff comprising an emulsifier, wherein the emulsifier is produced without increasing or without substantially increasing the free fatty acids in the foodstuff, and wherein the emulsifier is generated from constituents of the food material by the lipid:sterol acyltransferase.
12. Use according to claim 11 wherein either a sterol ester or a stanol ester is also produced *in situ* in the foodstuff.
13. Use according to claim 11 or claim 12 wherein a second emulsifier is also produced *in situ* in the foodstuff.
14. Use according to claim 12 wherein the sterol ester is one or more of alpha-sitosterol ester, beta-sitosterol ester, stigmasterol ester, ergosterol ester, campesterol ester or cholesterol ester.
15. Use according to claim 12 wherein the stanol ester is one or more beta-sitostanol or ss-sitostanol.
16. Use according to any one of claims 11 to 15 wherein the lipid:sterol acyltransferase is characterised as an enzyme which possesses acyl transferase activity and which comprises the amino acid sequence motif GDSX, wherein X is one or more of the following amino acid residues L, A, V, I, F, Y, H, Q, T, N, M or S.
17. Use according to any one of claim 11-16 wherein the lipid:sterol acyltransferase enzyme comprises H-309 or comprises a histidine residue at a

position corresponding to His-309 in the amino acid sequence of the *Aeromonas hydrophila* lipolytic enzyme shown as SEQ ID No. 2.

18. Use according to any one of claim 11-17 wherein the lipid:sterol acyltransferase is obtainable from an organism from one or more of the following genera: *Aeromonas*, *Streptomyces*, *Saccharomyces*, *Lactococcus*, *Mycobacterium*, *Streptococcus*, *Lactobacillus*, *Desulfitobacterium*, *Bacillus*, *Campylobacter*, *Vibrionaceae*, *Xylella*, *Sulfolobus*, *Aspergillus*, *Schizosaccharomyces*, *Listeria*, *Neisseria*, *Mesorhizobium*, *Ralstonia*, *Xanthomonas* and *Candida*.
19. Use according to any one of claims 11-18 wherein the lipid:sterol acyltransferase comprises one or more of the following amino acid sequences: (i) the amino acid sequence shown as SEQ ID No. 2; (ii) the amino acid sequence shown as SEQ ID No. 3; (iii) the amino acid sequence shown as SEQ ID No. 4; (iv) the amino acid sequence shown as SED ID No. 5; (v) the amino acid sequence shown as SEQ ID No. 6; (vi) the amino acid sequence shown as SEQ ID No. 12; (vii) an amino acid sequence which has 75% or more identity with any one of the sequences shown as SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 4, SEQ ID No. 5, SEQ ID No. 6 or SEQ ID No. 12.
20. Use according to any one of claims 11-19, wherein the second emulsifier is one or more of the following: a monoglyceride or a lysophosphatidylcholine.
21. A foodstuff obtainable by the method according to any one of claims 1-10.

ABSTRACT**METHOD**

A method for the *in situ* production of an emulsifier in a foodstuff, wherein a lipid:sterol acyltransferase is added to the foodstuff. Preferably the emulsifier is
5 produced without an increase or without a substantial increase in the free fatty acid content of the foodstuff. Preferably, in addition to the emulsifier either a stanol ester or a stanol ester may be produced.

Figure 1

SEQ ID No. 1

```

1 ivaGDSltD geayygsdsg gwgagladr ltallrlrar prgvdvfnrg isGrtsdGrl
61 ivDaivallF laqslqipnl pFtLsgdflr GANFAsagAt Ilptsgpfli QvqFhifksq
121 vlelrqalgl lqellrllpv ldakspdlvt imistwilit saffgpkste sdrnsvvpef
181 kdnlrqlikr lrsnmgarii vlitlviilnl gplGClPlkl alalassknv dasgclerln
241 eavadfneal relaiskled qlrkdgldpv kgadvpyvDl ysifqlddgi qnpsayvyGr
301 ettkaCCGyG gryWynrvCG naglcnvtak aCnpssylls flfwDgfHps ekGykavAea
361 1

```

Figure 2

SEQ ID No. 2

```

1 mkkwfvcllg lvaltvqaad xrpafsrivm fgdsldstgk myskmrgyly sspyyegrf
61 sngpwwleql tnefppltia neaeggptav aynkiwnpk yqvinnldye vtqflqkdsf
121 kpddlvilwv gandylaygw nteqdakrvr daidsaanrm vlnakgill fnlpldgqnp
181 sarsqkvvea ashvsayhnq lllnlarqla ptgmvkifei dkqfaemlrd pqnfglsdqr
241 nacyggyvw kpfasrsast dsqlsafnpq erlaiagnpl laqavaspma arsastlnce
301 gkmfwdqvhv ttvhaalse paatfiesqy eflah

```

Figure 3

SEQ ID No. 3

```

1 mkkwfvcllg lialtvqaad trpafsrivm fgdsldstgk myskmrgyly sspyyegrf
61 sngpwwleql tkqfppltia neaeggatav aynkiwnpk yqvynnldye vtqflqkdsf
121 kpddlvilwv gandylaygw nteqdakrvr daidsaanrm vlnakgill fnlpldgqnp
181 sarsqkvvea vshvsayhnk lllnlarqla ptgmvkifei dkqfaemlrd pqnfglsdve
241 npcydgyvw kpfatrsvt drqlsafnpq erlaiagnpl laqavaspma rrsasplnce
301 gkmfwdqvhv ttvhaalse raatfietqy eflahg

```

Figure 4

SEQ ID No. 4

```

1 mpkpalrrvm tatvaavgtl algltdatab aapagatptl dyvalgdsys agsgvlpvdp
61 anlcllrsta nyphviadt garltdvtcg aagtadfta qypgvapqld algtgdlvt
121 ltiggnnst finaitacgt egvlsaggks pckdrhgtsf ddeieantyp alkeallgvr
181 arapharvaa lgywitpat adpsclkip laagdvpplr aigahlndav rraaeetgat
241 yvdfsgvsdy hdaceapgtr wieplifghs lvpvhpnaig ermaehtmd vlgld

```

Figure 5

SEQ ID No. 5

1 mpkpalrrvm tatvaavgtl algltdatsh aapagatptl dyvalgdsys agsgvlpvdp
 61 anllclxsta nyphviadtt garltdvtcg aagtadfta qypgvapqld algtgtdlvt
 121 ltiggnadst finaitacgt agvlsggkgs pckdrbgtst ddeieantyp alkeallgvr
 181 arapharvaa lgywtpat adpscfklp laagdvpplr aigahlnlav rraaetgat
 241 yvdfsgvsdg bdaceapgr wiepllfghs lvpvhpmlg ermaehtmd vlgld

Figure 6

SEQ ID No. 6

1 mdyekfllfg dsitefafnt rpiedgkdqy algaalvney trkmdilqrg fkgysrwal
 61 kilpeilkhe snivmatifl gandacsagg qsvlpefid nirqmvslmk syhirpiig
 121 pglvdrekwe kekseeialg yfrtnenfai ysdalaklan eekvpfvaln kafqeggsda
 181 wqqlldgln fsgkgykifh dellkvietf ypyyhpkmq yklkdwrdvl ddgsnims

Figure 7

Alignment of pfam00657.6 consensus sequence with P10480

```

*-->ivaFGDSLfdg.....eayygdsgggwgagladrl
iv+fgDSL+d+++ ++ ++ ++++++ ++t+g w +tl + +
P10480 28 IVMPGDSLSDTgkmayskargylpssppYYEGRFSGFVWLEQLTNSF 74

tall..rlrarprgvdvfnrgisGrtsdGrllvDlvalIFlagslglpn
+ l + ++++++ +n+ +
P10480 75 PGLrIaNEAEGGPTAVAYNKISWNPK----- 100

lpPYLsgdflrGANFasagAtIlptsgpfliQvqfKdfksqvlrlrqalg
++ ++
P10480 101 -----YQVIMN 106

llqellrllpvladakspdlvtimiGtNDlitsaffgpkstesdrnsvsve
l++t+ ++l +++ k+ dl+++++G+ND+ ++ ++ ++++++
P10480 107 LDYEVTQFLQKDSFPPDLVLWVGANPY-----LAYGWNTEQDAKR 148

fkdnlrqlikrIrsnngariivlitlviilnlgpIGCLPiklalalasskn
++d ++++++r+ ngat ++++++l+ lG+ P+
P10480 149 VRDAISDAARNV-LNGAK-----ETLLFNLPLGLGQPS----- 181

vdasgclerlneavadfnealrelaiskledqlrkdgldpvtkgadpvyvD
+++ +e + ++t++n++l +la +ql+++g+++++d +q+
P10480 182 ARSQRVVEAASHVSAYHNQLLNLAL-----RQLAPTGMVKLFELDEQFAE 226

lysifgdldlgimpsayv.y....GFe.ttkaCCGyGgr.yNyn.rv.CG
+ +q+++ + + +a+++++ ++ ++++++ ++++++ +
P10480 227 MLRDPQWFLGSLDQKACyGyGyvvXFFaSRASSTDSQLSaFNQoERLaIA 276

nag.l.c.nvtakaC.npssyll.sflfwDgfHpskGykavheal<+
+++ l + ++++++ +t ++++++fvD+H+ ++a e
P10480 277 GNFLlaQvASPMARASASTLCEGMEFVDVHFPTTVVBAALSEPA 322

```

Alignment of pfam00657.6 consensus sequence with AAG09804

```

**>ivafGDSlTdg.....eayygdsdgggwgagladrL
iv+fGDSl+d+++ ++ ++ ++++++ ++s+g w +t+ + +
AAG09804      28  IVERGDSLSDTgkmyskmrgypspplTYEGRFSNGPVLQLTKQF 74

tallrlrarprgydvfnrgisGrtsdGrIivDalvallFlaqlglpnlp
+g+++ n + +G+t
AAG09804      75  -----PGLTIANEAEGGAT----- 88

PYLsgdfIrgANFasagAtIltsgpfliQvqFkdksqvlrlrga....
++++ + ++++ +
AAG09804      89  -----AVAYNKISWbpykq 102

..lgllqellrlpvlidakspdlvtimlGtNDlitsaffgpktsedrwn
+t+l++t+ t+l +++ k+ dlv++++G+ND+ ++ ++ ++
AAG09804      103 vYbELDYEVTFQfLQDSFKPDOLVILNVGANDY-----LAYGMTEQ 144

svpefkdmrlrqlrlrLsnngariivlitlviInlqplGClPlklalala
+++++d ++++++r nga+ +++++nl+ lG+ p+
AAG09804      145 DAKRVRDAISDAANRMV-LNGAK-----QILLFNLPLGQNPFS----- 181

ssknvdasgclerlneavadfnealrelaiskledqlrkdglpdkvgadv
+++ +s + +s+atn+t+ tla +gl+++g+++++d
AAG09804      182 -----ARSQKVVEAVSHVASYHNKLLNLNLA-----ROLAPTGMVKLEIDR 222

pyvDlysifqdlgiqmpsayv.y....GFe.ttkaCCGyGqr.yWyn.r
++++ +g+++ + ++ +++++ ++ t++ ++ ++ ++ + +tr
AAG09804      223 QFAELRLDPQMFGLSDVENPCYdggywKFPaTrSVSTDRQLSaFSQPQeR 272

v.CGdag.l.c.nvtakaC.npssyll.3sflwDgfHpsckGykavAeal
+ +++++ l + +++++at+ +s ++++++fwd+H+p+ ++a+ e+
AAG09804      273 LaIAGNPLlaQVASPMARCSASPLNCeGKMFDQVHP-TVVbAALSErA 322

```

Figure 7 cont'd

AAG09804

Alignment of pfam00657.6 consensus sequence with NP_631558

```

*->ivafGDSltDgeayygdsgggwgagladrltallrlrarprgvdvf
+va+GDS ++g      +g + +++L  + + + + +
NP_631558  42  YVALGDSYSAG-----SGVLPVDFANL-----LCLRSTANYPHV 75

nrgisGrtsdGrliVd.a.l.vallFlaqlglpnlPYLsgdflrGANP
+ ++G++      D + + +
NP_631558  76  IADTTGAR-----LTDvTcGaAQ-----93

AsagAtIlptsgpfliQvqFkdfksqvlrlqalglgellrllpvlak
+++ ++ + ++ +
NP_631558  94  -----TADFTRAQYPGVAPQLDALGT 114

spdlvtimiGtNDL.....itsaffgpkstesdrnvsvp
+ dlvt+ iG+ND ++ + + ++ + ++ + +k ++ + ++
NP_631558  115 GTDLVTLTIGGNDNstfinaitacgtagvLSGGKGSFCKDRHGTSFDDEI 164

efkdn..lrqlikrLrs.nngariivlitlvilnlg.....plG
e +++ l++++ +r+++ +ar+ +l ++i+++ +++ + + G
NP_631558  165 EANTYpalKEALLGVRARAPHARVAALGYPWITPATadpscflklplAAG 214

ClPlklalalassknvdasgclerlneavadfnealrelaiskledqlrk
P+      l+ ++a n a+r a
NP_631558  215 DVFY-----LRAIQAHLEDAVRRRA-----234

dglpdkgadpvyvDlysfqldgignpsayvyGFettkaCCGyGgryN
++ + +yvD+ ++
NP_631558  235 -----EETGATTVDVDFSGVSDG-----250

ynrvCGnaglcmtakaC.npssyll.sflwDgf...EpsekGykavAe
++aC+ p +++ + lf + + + Bp++ G +++Ae
NP_631558  251 -----HDACeAPGTRWTePLLFCHSLvpvBPNALGERRMAE 286

al<-*
+
NP_631558  287 HT 288

```

Alignment of pfam00657.6 consensus sequence with CAC42140

```

*->ivafGDSltDgeayygdsgggwgagladrltallrlrarprgvdvf
+va+GDS ++g      +g + +++L  + + + + +
CAC42140  42  YVALGDSYSAG-----SGVLPVDFANL-----LCLRSTANYPHV 75

nrgisGrtsdGrliVd.a.l.vallFlaqlglpnlPYLsgdflrGANP
+ ++G++      D + + +
CAC42140  76  IADTTGAR-----LTDvTcGaAQ-----93

AsagAtIlptsgpfliQvqFkdfksqvlrlqalglgellrllpvlak
+++ ++ + ++ +
CAC42140  94  -----TADFTRAQYPGVAPQLDALGT 114

spdlvtimiGtNDL.....itsaffgpkstesdrnvsvp
+ dlvt+ iG+ND ++ + + ++ + ++ + +k ++ + ++
CAC42140  115 GTDLVTLTIGGNDNstfinaitacgtagvLSGGKGSFCKDRHGTSFDDEI 164

efkdn..lrqlikrLrs.nngariivlitlvilnlg.....plG
e +++ l++++ +r+++ +ar+ +l ++i+++ +++ + + G
CAC42140  165 EANTYpalKEALLGVRARAPHARVAALGYPWITPATadpscflklplAAG 214

ClPlklalalassknvdasgclerlneavadfnealrelaiskledqlrk
P+      l+ ++a n a+r a
CAC42140  215 DVFY-----LRAIQAHLEDAVRRRA-----234

dglpdkgadpvyvDlysfqldgignpsayvyGFettkaCCGyGgryN
++ + +yvD+ ++
CAC42140  235 -----EETGATTVDVDFSGVSDG-----250

ynrvCGnaglcmtakaC.npssyll.sflwDgf...EpsekGykavAe
++aC+ p +++ + lf + + + Bp++ G +++Ae
CAC42140  251 -----HDACeAPGTRWTePLLFCHSLvpvBPNALGERRMAE 286

```

Figure 7 cont'd

```

                                al<-*
                                +
CAC42140 287 HT 288
5
Alignment of pfam00657.6 consensus sequence with P41734
*->ivafGDSITdg....eayygdsgggwgagladrLtallrlrarprg
++fGDS+T+ +++ + + d+ ga+l + + ++r+
10 P41734 6 FLLFGDSITEPafntRPIEDGKDQYALGAALVNEY-----TRK 43
vdfnrgisGrtsdGrliVdallFlagslglpnLpPYLsgdfLrGAN
+d+ rg++G+t
P41734 44 NDILORGFGKGYT----- 55
15 FAsagAtIlptsgpfliQvqFkdfksqvlrlrgalglgellrllpvlda
+r+al++l+e+l+ +
P41734 56 -----SRWALKILPEILKH-----E 70
kspdlvtimiGtNDlitsaffgpkstesdrnsvpefkdnrlqlikrLrs
+ + ti++G+ND+ ++ +++ v++pef+dn+rq+++++s
20 P41734 71 SNIVMATIFLGANDA-----CSAGQSVPLPEFIDNIROMVSLMRS 111
nngariivlitlivilnlglpIGClPlklalalasskrvdasgcierlneav
++++ii++++lv ++ ++ k ++ + + r+ne +
25 P41734 112 YHIRPIIIGPGLVDREKW-----EKEKSEELALGYFRTNENF 148
adfnearlaaiskledqlrkdgldpdkgadvpyvDlysifgdldgimp
a + al +la ++ +vp+v l+++fq+ +g++++
30 P41734 149 AIYSDALAKLA-----NEEKVPPFVALNKAFQEGGDANQ 182
sayvyGFettkaCCGyGgryNynrvCGnaglcnvtakaCnpssyllsflf
+ 1+
P41734 183 Q-----LL 185
35 wDgfHpssekGykavAeal<-*
Dg+H+s kGyk+++++l
P41734 186 TDGLHFSGKGYKIFHDEL 203

```

Figure 8

```

A.sal 1  MKKWFVCLLGLIALTVQAADTRPAFSRIVMFEEDSLSDTGKMYSKMRGYLPSSPPYIEGRF 60
          +          +
A.hyd 1  MKKWFVCLLGLVALTVQAADSRPAFSRIVMFEEDSLSDTGKMYSKMRGYLPSSPPYIEGRF 60
          +          +
A. sal 61  SNGPVMLEQLTKQFPGLTIAEAEGGATAVAYNKISWNPKYQVINNLQYEVTQFLQKDSF 120
          ++          +
A. hyd 61  SNGPVMLEQLTNEFPGLTIAEAEGGPTAVAYNKISWNPKYQVINNLQYEVTQFLQKDSF 120
          ++          +
A. sal 121 KPDDLVLVVGANDYLAYGWTEQDAKVRDAISDAANRMVINGAKQILLFNLPLDIGNP 180
          +
A. hyd 121 KPDDLVLVVGANDYLAYGWTEQDAKVRDAISDAANRMVINGAKEILLFNLPLDIGNP 180
          +
A. sal 181 SRSQKVVEAVSHVSAYHNKLLLNARQLAPTGMVKLFEIDKQFAEMLRDPQNFGLSDVE 240
          +          +
A.hyd 181 SRSQKVVEAASHVSAYHNQLLLNARQLAPTGMVKLFEIDKQFAEMLRDPQNFGLSDQR 240
          ++
A. sal 241 HPCYDGGYVWKPFATRSVSTDRQLSAFSPQERLAIAGNPLLAQAVASPMARRSASPLNCE 300
          + + + + + + + + + +
A. hyd 241 HACTGGSYVWKPFASRSASTDSQLSAFNPQERLAIAGNPLLAQAVASPMARRSASTLACE 300
          + + + + + + + + + +
A. sal 301 GRMFWDQVHPPTTVVHAALSEAATFETQYEFLAH 335
          +          +
A. hyd 301 GRMFWDQVHPPTTVVHAALSEPAATFIESQYEFLAH 335

```

Figure 9

```

1  ATGAAAAAT GGTTCGTG TTTATTGGGA TTGGTCGGGC TGACAGTTCA GGCAGCCGAC
61  AGCCGTCCCG CCTTCTCCCG GATCGTGATG TTTGGCGACA GCCTCTCCGA TACCGGCAAG
121 ATGTACAGCA AGATGCGCGG TTACCTCCCC TCCAGCCCCC CCTACTATGA GGGCCGCTTC
181 TCCAACGGGC CCGTCTGGCT GGAGCAGCTG ACCAACGAGT TCCCGGGCCT GACCATAGCC
241 AACGAGGCGG AAGGCGGACC GAGCCCGGTG GCTTACAACA AGATCTCCTG GAATCCCAAG
301 TATCAGGTCA TCAACAACCT GGACTACGAG GTCACCCAST TCTGCAAAA AGACAGCTTC
361 AAGCCGGACG ATCTGGTGAT CCTCTGGGTC GCGGCCAAGC ACTATCTGGC CTATGGCTGG
421 AACACAGAGC AGGATGCCAA GCGGCTGGCG GAGGCCATCA GCGATGCGGC CAACCGCATG
481 GTGCTGAACG GCGCCAAGGA GATACTGCTG TTCAACCTGC CGGATCTGGG CCAGAACCCC
541 TCGGCCCGCA GCCAGAGGT GGTGAGGCGG GCCAGGCATG TCTCCGCCTA CCACAACCAG
601 CTGCTGCTGA ACCTGGCAGC CCAGCTGGCT CCCACCGGCA TGGTGAAGCT GTTCSAGATC
661 GACAGCAGT TTGCCGAGAT GCTGCGTGAT CCGCAGAACT TCGGCCTGAG CGACCAAGAG
721 AACGCTTGCT ACGGTGGCAG CTATGTATGG AAGCCGTTG CCTCCCGCAG CGCCAGCACC
781 GACAGCCAGC TCTCCGCTT CAGCCCGCAG GAGCGCTCG CCATCGCCGG CAACCCGCTG
841 CTGGCCAGG CCGTGGCCAG CCCATGGCT GCGCGCAGCG CCAGCACCTT CAACTGTGAG
901 GGCAAGATGT TCTGGGATCA GGTCCACCCC ACCACTGTG TGCAGCGCCG CCGTGGCGAG
961 CCGCCGCCA CCTTCATCGA GAGCCAGTAC GAGTTCTCG CCCAC

```

Figure 10

```

1  ATGAAAAAT  GGTITGTTG  TTTATTGGG  TTGATCGCG  TGACASTTCA  GGCAGCCGAC
61  ACTCGCCCG  CCTTCTCCG  GATGCTGAT  TTCGGCGCA  GCCTCTCCG  TACCGGCAAA
121  ATGTACAGCA  AGATGCGCG  TTACCTCCC  TCCAGCCCG  CCTACTATGA  GGGCCGTTTC
181  TCCAACGAC  CCGTCTGGT  GGAGCAGCT  ACCAAGCAGT  TCCCGGGTCT  GACCATCGCC
241  AACGAAGCG  AAGGCGGTG  CACTGCCGT  GCTTACAACA  AGATCTCCT  GAATCCCAAG
301  TATCAGGCT  ACAACAACCT  GGACTACGAG  GTCACCCAGT  TCTTGCAGAA  AGACAGCTTC
361  AAGCGGAGC  ATCTGGTGT  CCTCTGGGT  GGTGCCAATG  ACTATCTGG  ATATGSGCTG
421  AATACGGAG  AGGATGCCAA  GCGAGTTCG  GATGCCATCA  GCGATGCGG  CAACCGCATG
481  GTACTGAAG  GTGCCAAGCA  GATACTGCT  TTCAACCTG  CGGATCTGG  CCAGAACCCG
541  TCAGCCCGCA  GTCAGAAGT  GGTGAGGCG  GTCAGCCAT  TCTCCGCTA  TCACAACAAG
601  CTGCTGCTA  ACCTGGCAG  CCGCTGGCC  CCCACCGCA  TGGTAAAGT  GTTCGAGATC
661  GACAAGCAAT  TTGCCGAGT  GCTGCGTGT  CCGCAGAACT  TCGGCTGAG  CGACGTCGAG
721  AACCCCTGT  ACGACGGCG  CTATGTGTG  AAGCCGTTT  CCACCCGCG  CGTCAGCACC
781  GACCGCCAG  TCTCCGCTT  CAGTCCGAG  GACCGCTCG  CCATCGCCG  CAACCCGCTG
841  CTGGCACAG  CCGTTGCCG  TCCTATGGC  CGCCGAGCG  CCAGCCCTT  CAATCTGTAG
901  GGCAAGATGT  TCTGGGATCA  GGTACACCC  ACCACTGTC  TGCACGCAG  CCTGAGCGAG
961  CGCGCCGCC  CCTTCATCA  GACCCAGTAC  GAGTTCTCT  CCCACGGAT  A

```

Figure 11

```

1  ATGCGGAGC CTGCCCTTCG CCGTGTATG ACGCGACAG TCGCCGCCGT CGGCACGCTC
61  GCGCTGGGCC TCACCGACGC CACCGCCAC GCGCGGCCG CCCAGGCCAC TCGACCCCTG
121 GACTACGTGC CCTCGGCCA CAGCTACAG GCGGCTCCG GCGTCTGCG CGTCGACCCC
181 GGCACCTGC TCTGTCTGCG CTCGACGGC AACTACCCC ACGTCATCG GGCACGACG
241 GCGGCCCGCC TCACGGACGT CACCTGCGGC GCGCGCCAG CCGCCGACTT CACGCGGGCC
301 CAGTACCCGG GCGTCGCACC CCAGTTGGAC GCGCTCGCA CCGGCACGGA CCTGGTCAAG
361 CTCACCATCG GCGGCAACGA CACAGCACC TTCATCAAG CCATCACGGC CTGCGGCACG
421 GCGGGTGTCC TCAGCGGCGG CARGGCAGC CCTGCBAGG ACAGGCACGG CACCTCCTTC
481 GACGACGAGA TCGAGGCCAA CACGTACCCC GCGCTCAAG AGCGCTGCT CCGCGTCGCG
541 GCGAGGGCTC CCCACGCCAG GGTGGCGGCT CTGCGCTACC CGTGGATCAC CCCGGCCACC
601 GCGGACCCGT CCTGCTTCCT GAAGCTCCCC CTGCGCGCG GTCAGGTGCC CTACCTGCGG
661 GCCATCCAGG CACACCTCAA CGACGCGGTC GCGCGGGCG CCGAGGAGAC CCGAGCCACC
721 TACGTGGACT TCTCCGGGGT GTCCGACGGC CACGACGCT GCGAGGCCCG CCGCACCCGC
781 TGGATCGAAC CGCTGCTCTT CCGGCACAGC CTCGTTCCG TCCACCCCAA CCGCCTGGGC
841 GAGCGCGCA TGGCCGAGCA CACGATGGAC GTCTCGGCC TGGACTGA

```

Figure 12

```

1  TCACTCCAGG CCGAGGACGT CCATCSTGTG CTCGGCCATG CCGCGCTCCG CCAGGGCGTT
61  GGGGTGGACG GGAACGAGGC TGTGCCCGAA GAGCAGCGGT TCGATCCAGC GGGTGCOCGG
121  GGCTTCGCAG GCGTCTGGC CGTCCGACAC CCGGAGAGG TCCACGTAGG TGGCTCOCGT
181  CTCTCGGCG GCGCGCCGGA CCGCGTCTT GAGGTGTGCC TGGATGGCC GCAGGTAGGG
241  CACGTCAACG GCGGCGAGGG GGAGCTTCAG GAAGCAGGAC GGGTCGGCGG TGGCCGGGT
301  GATCCACGGG TAGCCGAGAG CCGCCACCTT GCGTGGGGA GCGTGGCGC GGAACCGGAG
361  CAGCGCTCC TTGAGCGCGG GGTACGTGTT GCGCTGATC TCGTGTCCA AGGAGGTGCC
421  GTCCCTGTCC TTGCAGGGGC TGCCCTTCCC GCGCTGAGG ACACCCGCCG TGCCGCAGGC
481  CGTGATGGCG TTGATGAAGG TGCTGTGTG GTTGCCGCCG ATGGTGAGCG TGACCAAGTC
541  CGTGCCGGTG CCGAGCCCGT CCAACTGGGG TCGACGCCCC GGGTACTGGG CCGCGTCAA
601  GTCCGCCGTC TCGCGCGCGC CCGAGGTGAC GTCCGTGAGG CCGGCGCCCG TCGTGTCCGC
661  GATGACGTGG GGGTAGTTGG CCGTCGAGCG CAGACAGAGC AGGTGGCGG GGTCCAGGG
721  CAGGACGCCG GAGCCGCCGC TGTAGCTGTC GCGAGGGCG ACGTAGTCCA GGGTCGGAGT
781  GCGCTGGCGG GCGCGCGCGT GCGCGGTGGC GTCGGTGAGG CCGAGGGCGA GCGTGCOCGAC
841  GCGGCGGACT GTCGCGGTCA TGACAGCGCG AAGGGCAGGC TTCGGCAT

```

Figure 13

```

1  ATGGATTACG AGAAGTTTCT GTTATTTGGG GATTCCATTA CTGAATTTGC TTTTAATACT
61  AGGCCCCATTG AAGATGGCAA AGATCAGTAT GCTCTTGGAG CCGCATTAGT CAACGAATAT
121  ACGAGAAAAA TCGATATTCT TCAAGAGGGG TTCAAAGGGT ACACTTCTAG ATGGGCGTTG
181  ABAATACITC CTGAGATTIT AAAGCATGAA TCCAATATTG TCATGGCCAC AATATTTTGG
241  GGTGCCACCG ATGCATGCTC AGCAGGTCCC CRAAGTGTCC CCTCCCCGA ATTTATCGAT
301  AATATTCGTC AATGCTATC TTTGATGAG TCTTACCATA TCCGTCTAT TATAATAGGA
361  CCGGGGCTAG TAGATAGAGA GAAGTGGGAA AAAGAAAAAT CTGAAGAAAT AGCTCTCGGA
421  TACTTCCGTA CCAACGAGAA CTTTGGCATT TATTCCGATG CCTTAGCAAA ACTAGCCAT
481  GAGGAABAAAG TTCCCTTGTG GCTTTGAAT AAGGCGTTTC AACAGGAAGG TGGTGATGCT
541  TGGCAACAAC TGCTAACAGA TGGACTGCAC TTTTCCGGAA AAGGGTACAA AATTTTTCAT
601  GACGAATTAT TGAAGGTCAI TGAGACATTC TACCCCAAT ATCATCCCAA AATCATGCAG
661  TACAAACTGA AAGATTGGAG AGATGTGCTA GATGATGGAT CTAACATAAT GTCTTGA

```

12/14

Figure 14

(SEQ ID No. 12)

10	20	30	40	50	60
MNLRQRMGAA	TAALALGLAA	CGGGGTDQSG	NPNVAKVQRM	VVFGDSLSDI	GYTPVAQAV
70	80	90	100	110	120
GGGKPTTNP	PINAETVAAQ	LGVTLPVAV	GYATSVQVCP	KAGCFDYAQG	GSRVTDPMGI
130	140	150	160	170	180
GHNGGAGALT	YFVQQQLANF	YAASWETPFG	NDVVFVLAS	NDIPFWTTA	AATSGSGVTP
190	200	210	220	230	240
AIATAQVQQA	ATDLVGYVKD	MIKGTQVY	VFNLPDSSLT	PDGVASGTTG	QALLHALVGT
250	260	270	280	290	300
FNTTLQSGLA	GYSARIIDFN	AQLTAAIQNG	ASFGFANTSA	RACDATKINA	LVPSAGGSSL
310	320	330	340		
FCSANTLVAS	GADQSYLFAD	GVHPTTAGHR	LIASNVLARL	LADNVAH	

Figure 15

(SEQ ID No. 13)

atgaacctgc gtcaatggat gggcgccgcc acggctgccc ttgccttggg cttggccgcg	60
tgccggggcg gtgggaccga ccagagcggc aatcccaatg tcgccaaggt gcagcgcag	120
gtggtgttcg gcgacagcct gagcgatata ggcacctaca ccccgctcgc gcaggcggty	180
ggcggcggca agttcaccac caaccggggc ccgatctggg ccgagaccgt ggcgcgcgaa	240
ctgggcgtga cgttcacgce ggcggtgatg ggctaagcca cctccgtgca gaattgcccc	300
aaggccggct gcttcgacta tgcgcagggc ggctcgcgcg tgaccgatcc gaacggcatc	360
ggccacaacg gcggcgcggg ggcgctgacc taccgggttc agcagcagct cgccaacttc	420
tacgcggcca gcaacaacac attcaacggc aataacgatg tcgtcttcgt gctggccggc	480
agcaacgaca ttttcttctg gacctctgcg gcggccacca gcggctccgg cgtgacgccc	540
gccattgcca cggcccaggt gcagcaggcc gcgacggacc tggtcgggta tgtcaaggac	600
atgatcgcca aggggtcgac gcaggtctac gtgttaacc tgcgcgacag cagcctgacg	660
ccggacggcg tggcaagcgg caccagcggc caggcgctgc tgcaacgcgt ggtgggcacg	720
ttcaacacga cgtgcgaaag cgggctggcc ggcacctcgg cgcgcacat cgacttcac	780
gcacaactga ccgcggcyat ccagaatggc gcctcgttcg gcttcgccaa caccagcggc	840
cgggcctgcg acgccacca gateaatgcc ctggtgcca gcgccggcgg cagctcgctg	900
ttctgctcgg ccaacacgct ggtggcttcc ggtgcggacc agagctacct gttcgccgac	960
ggcgtgcacc cgaccacggc cggccatcgc ctgatcgcca gcaactgct ggcgcgctg	1020
ctggcggata acgtcgcgca ctga	1044

Figure 16

	1	10	20	30	40	50

satA	ADTRPAFSRIVHFGDSLSDTGKMYSKIRGYLPSSPPYYEGRFSH—G					
R.sol	QSGNPVAKYQRMVVFGLSDIGT-----YTPVAQAVGGGKFTTNPG					
Consensus	...adnraafqRiVnFGDSLSDIGk.....YIPsaqaygegrFsn..G					
	51	60	70	80	90	100

satA	PVHLEQLTKQFPGLTIANEREGGATAVAYNKISNPKYQVINMLDYEVTQ					
R.sol	PINAEIVAAQL—GVTLTPAVMGYATSVQNCPKAGCFDYAQGGSKYTDPNQ					
Consensus	P!NaEqlaaQL.6LTianaaeGgaTaVannkiagnfdYaggnrnt.#pnq					
	101	110	120	130	140	150

satA	FLQKDSFKPDDLVLNMGANDYLAYG--WTEQDAKRYRDAISDAANRY					
R.sol	IGHNGGAGALTYPVQQQLANFYASNNTFNGNNDVYFVLAGSNDIFFHTT					
Consensus	igqndgagaddlp!qqqgRNdYafsn..fNg##DakrVraainDaanrnt					
	151	160	170	180	190	200

satA	LNGAKQTLLENLPLDGNPSARSQKYVERVSHVSAHYHKL—LLNLARQLA					
R.sol	AARTSGSGYTPAIAAQVQQAATDLVGYVKDILAKGATQYVYFNLPDSSL					
Consensus	aaaakqiglfnaialaQnqqqHas#lvgeakdh!aaganql.11NLArqla					
	201	210	220	230	240	250

satA	PTGMVKLFEDKQFAEMLRDPQNFGLSDVENPCYDGGYVWKPFATRVSST					
R.sol	TPDGVASGTTGQALLHALVGTFTTLQSGLAGTSARITDFNAQLTAAIQH					
Consensus	ppdgValgeidqalaealrdpqHfqlqdeagcsargidfnagaTaa!qn					
	251	260	270	280	290	300

satA	DRQLSAFSPQERLAIG—NPLLAQAVASPM—ARRSASPLNCEGKJFH					
R.sol	GASFGFANT SARACD ATKINALVPSAGGSSLFCSANTLVASGADQSYLFA					
Consensus	daqlgaanpqaRaadAg..NaLlaqHgaSp\$...Arrlaapgad#gk\$Fa					
	301	310	320	330		

satA	DQVHPTTVVHAALSERATFTIETQYEFLAH					
R.sol	DGVHPTTAGHRLTASHVLARLLA—DNVAH					
Consensus	DqVHPTTagHaaiaeraaariae..#nLAH					

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.